





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) INT


(51) International Patent Classification ⁵ : A61K 31/435, C07D 221/02	A1	(11) International Publication Number: WO 93/23038 (43) International Publication Date: 25 November 1993 (25.11.93)
(21) International Application Number: PCT/US93/04633 (22) International Filing Date: 17 May 1993 (17.05.93) (30) Priority data: 886,057 20 May 1992 (20.05.92) US (60) Parent Application or Grant (63) Related by Continuation US 886,057 (CIP) Filed on 20 May 1992 (20.05.92) (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only) : WITZEL, Bruce, E. [US/US]; 115 Scotch Plains Avenue, Westfield, NJ 07090 (US). BERGMAN, Jeffrey, P. [US/US]; 33 South Street, Ridgefield Park, NJ 07660 (US). TOLMAN, Richard, L. [US/US]; 29 Upper Warren Way, Warren, NJ 07059 (US). (74) Agent: GRASSLER, Frank, P.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: 17-AMINO SUBSTITUTED 4-AZASTEROID 5 α -REDUCTASE INHIBITORS


(I)



(a)



(b)



(c)

(57) Abstract

Novel amino substituted 4-azasteroid 5 α -reductase inhibitors of formula (I), wherein A is (a), (b) or (c), are claimed as well as pharmaceutically acceptable salts and formulations thereof. These compounds are effective in inhibiting testosterone 5 α -reductase(s) and are thus useful in the treatment of a number of hyperandrogenic conditions including benign prostatic hypertrophy, acne, seborrhea, female hirsutism, and male and female pattern baldness (alopecia).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

TITLE OF THE INVENTION

17-AMINO SUBSTITUTED 4-AZASTEROID 5 α -REDUCTASE
INHIBITORS

5

BACKGROUND OF THE INVENTION

The present invention is directed to novel amino substituted 4-azasteroidal 5 α -reductase inhibitors.

10

15

20

The art reveals that certain undesirable physiological manifestations, such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness and benign prostatic hypertrophy, are the result of hyperandrogenic stimulation caused by an excessive accumulation of testosterone or similar androgenic hormones in the metabolic system. Early attempts to provide a chemotherapeutic agent to counter the undesirable results of hyperandrogenicity resulted in the discovery of several steroidal antiandrogens having undesirable hormonal activities of their own. The estrogens, for example, not only counteract the effect of the androgens but have a feminizing effect as well. Non-steroidal antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethyl-isobutyranilide. See Neri, et al., Endo., Vol. 91, No. 2 (1972). However, these products, though devoid of hormonal effects, are peripherally active, competing with the natural androgens for receptor sites, and hence have a tendency to feminize a male host or the male fetus of a female host.

25

30

It is now known in the art that the principal mediator of androgenic activity in some target organs is 5 α -dihydrotestosterone, and that it is formed locally in the target organ by the action of testosterone-5 α -reductase. It is also known that inhibitors of testosterone-5 α -reductase will serve to prevent or lessen symptoms of hyperandrogenic stimulation. A number of 4-azasteroid compounds are known in the art as 5 α -reductase inhibitors. For example, See U.S. Patent Nos. 2,227,876, 3,239,417, 3,264,301 and 3,285,918; French Patent No. 1,465,544; Doorenbos and Solomons, J. Pharm. Sci. 62, 4, pp. 638-640 (1973); Doorenbos and Brown, J. Pharm. Sci., 60, 8, pp. 1234-1235

(1971); and Doorenbos and Kim, J. Pharm. Sci. 63, 4, pp. 620-622 (1974).

In addition, U.S. Patent Nos. 4,377,584, 4,220,775, 4,859,681, 4,760,071 and the articles J. Med. Chem. 27, p. 1690-1701 (1984) and J. Med. Chem. 29, 2998-2315 (1986) of Rasmusson, et al., U.S. Patent 4,845,104 to Carlin, et al., and U.S. Patent 4,732,897 to Cainelli, et al. describe 4-aza-17 β -substituted-5 α -androstan-3-ones which are said to be useful in the treatment of DHT-related hyperandrogenic conditions.

However, despite the suggestion in the prior art that hyperandrogenic diseases are the result of a single 5 α -reductase, there are reports regarding the presence of other 5 α -reductase isozymes in both rats and humans. For example, in human prostate, Bruchovsky, et al. (See J. Clin. Endocrinol. Metab. 67, 806-816, 1988) and Hudson (see J. Steroid Biochem. 26, p 349-353, 1987) found different 5 α -reductase activities in the stromal and epithelial fractions. Additionally, Moore and Wilson described two distinct human reductases with peaks of activities at either pH 5.5 or pH 7-9. (See J. Biol. Chem. 251, 19, p. 5895-5900, 1976.)

Recently, Andersson and Russell isolated a cDNA which encodes a rat liver 5 α -reductase (see J. Biol. Chem. 264 pp. 16249-55 (1989). They found a single mRNA which encodes both the liver and prostatic reductases of rats. The sequence of this rat gene was later used to select a human prostatic cDNA encoding a 5 α -reductase termed "5 α -reductase 1". (See Proc. Nat'l. Acad. Sci. 87, p. 3640-3644, 1990.)

More recently, a second, more abundant reductase (5 α -reductase 2) has been cloned from human prostate with properties identified with the form found in crude human prostatic extracts. (See Nature, 354, p. 159-161, 1991.)

Further, "Syndromes of Androgen Resistance" - The Biology of Reproduction, Vol. 46, p. 168-173 (1992) by Jean O. Wilson indicates that the 5 α -reductase I enzyme may be associated with hair follicles.

- 3 -


Thus, the art supports the existence of at least two genes for 5 α -reductase and two distinct isozymes of 5 α -reductase in humans. Both forms are present in prostatic tissue in which, 5 α -reductase 2, is the more abundant, whereas the other isozyme, 5 α -reductase 1, is believed to be more abundant in scalp tissue.

In the treatment of hyperandrogenic disease conditions, e.g. benign prostatic hyperplasia (BPH) it would be desirable to have one drug entity which is active against both enzymes 1 and 2 in the prostate to substantially inhibit dihydrotestosterone (DHT) production. Alternatively, it would be desirable to have a drug entity which is highly selective for inhibiting the scalp associated enzyme 5 α -reductase 1, for use in treating diseases of the skin and scalp, e.g., acne and alopecia. This latter drug could thus be used in combination with PROSCAR® (finasteride) which is highly selective for the prostatic enzyme 5 α -reductase 2 for combination therapy in the treatment of BPH.

SUMMARY OF THE INVENTION

The present invention is concerned with novel 4-azasteroidal compounds and pharmaceutical compositions and formulations thereof that are useful for inhibiting the 5 α -reductase isozymes 1 and 2 and are particularly effective in selectively inhibiting the 5 α -reductase 1 associated with the scalp and dually inhibiting both isozymes 1 and 2 in the treatment of benign prostatic hyperplasia, acne, female hirsutism, male pattern baldness, androgenic alopecia, prostatitis, and the prevention and treatment of prostatic carcinoma.

The present invention is concerned with compounds of the formula:





- 4 -


I

and the pharmaceutically acceptable salts thereof, wherein:

A is:



except when R² equals H, there is a 5αH and W equals C(O). R³ can not be C₁-12 alkyl.



R¹ is:

H,
methyl or ethyl;

R² is:


H, or
C₁-20 alkyl;

R³ is:

H,
aminoC₁-C₄alkyl,
mono C₁-C₄alkylaminoC₁-C₄alkyl,
di C₁-C₄alkylaminoC₁-C₄alkyl,


- 5 -

mono C₁-C₄ alkylaminoaryl,
 di C₁-C₄ alkylaminoaryl,
 C₁-20 alkyl,
 5 C₆-14 aryl,
 heteroaryl,
 C₆-14 arylC₁-20alkyl,
 heteroarylC₁-20alkyl,
 C₁-20alkylthioC₁-20alkyl,
 10 C₁-20alkylsulfinylC₁-20alkyl,
 C₁-20alkyloxycarbonylC₁-20alkyl,
 carboxylC₁-20alkyl,
 C₁-20alkylcarbonylC₁-20alkyl,
 carboxylC₁-20alkyl,
 15 C₁-20alkylcarbonylC₁-20alkyl,
 C₃-20cycloalkyl,
 C₃-20cycloalkylC₁-20alkyl,
 C₆-14 arylC₁-20alkyloxycarbonylC₁-20alkyl,
 heteroarylC₁-20alkyloxycarbonylC₁-20alkyl,
 haloC₁-20alkyl,
 20 hydroxylC₁-20alkyl,
 halohydroxylC₁-20alkyl,
 thiosulfatoC₁-20alkyl,
 C₆-14 arylC₁-20alkyloxyC₁-20alkyl,
 C₁-20alkyloxyC₁-20alkyl,
 25 C₆-14 arylcarbonylC₆-14arylC₁-20alkyl,
 diarylC₁-20alkyl of the formula:



triarylC₁-20alkyl of the formula:

- 6 -



, n equals 1-19;

C2-20 alkenyl,

C2-20 alkenylC1-20alkyl,

heteroarylC2-20alkenyl,

C6-14 arylC2-20alkenyl,

C2-20alkynylC1-20alkyl,

C6-14 arylC2-20alkynylC1-20alkyl, or

heteroarylC2-20alkynylC1-20alkyl;

R⁴ is:

H,

C1-20 alkyl,

C₆ aryl wherein aryl is a monocyclic system composed of 6-membered aromatic rings either unsubstituted or substituted with R wherein R is H, C₁-6 alkyl, arylC₁-20alkyl with the alkyl groups unsubstituted or substituted with hydroxyl, C₁-8alkyloxy, carboxy C₀-10alkyl, or halogen or aryl directly substituted independently with amino, mono C₁-C₄ alkylamino, di C₁-C₄ alkylamino, mono C₁-C₄ alkylaminoaryl, di C₁-C₄ alkylaminoaryl, hydroxyl, haloC₁-20alkyl, carboxamido, benzoyl, C₁-20alkyloxy, C₁-20alkyl, C2-20alkenyl, cyano, nitro, acetamide, halogen or other specific groups as shown herein or

heteroaryl;

R⁵ can be the same or different when x is greater than 1 and is:

H, or


- 7 -

C₁-12 alkyl;
R⁷ or R⁸ are:

5 H,
 CH₃,
 C₂H₅,
 carboxamido,
 C₁-6 alkylthio,
10 C₁-C₆ alkylsulfinyl,
 C₁-C₆ alkylsulfonyl,
 OCH₃,
 NH₂,
 CH₃NH,
 (CH₃)₂N,
15 OH,
 NO₂,
 CN,
 F,
 acetamido,
20 Cl,
 OC₂H₅,
 CF₃,
 isopropyl, or
 isobutyl; n equals 1-10 and the C₁-20 alkyl portion is optionally
25 substituted with R⁵;

W is:

30 $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}- \end{array}$, or




- 8 -

x is an integer from 1-25;

and the dashes indicate a double bond is optionally present.




Advantageously, compounds of the following formula are disclosed:



I

and the pharmaceutically acceptable salts thereof, wherein:

A is:



R¹ is:

H,
methyl, or ethyl;

- 9 -

R² is:

5 H, or
 C₁-20alkyl;

R³ is:


10 H,
 C₁-20alkyl is a straight or branched chain alkane of up to 20
 carbon atoms;

15 C₆-14 aryl wherein aryl is a mono or polycyclic system
 composed of 6-membered aromatic rings either unsubstituted or
 substituted with R wherein R is H, C₁-6 alkyl, arylC₁-20alkyl
 with the alkyl groups unsubstituted or substituted with hydroxyl,
 C₁-8alkyloxy, carboxy C₀-10alkyl, or halogen or aryl directly
 substituted independently with amino, mono C₁-C₄ alkylamino, di
 C₁-C₄ alkylamino, mono C₁-C₄ alkylaminoaryl, di C₁-C₄
20 alkylaminoaryl, hydroxyl, haloC₁-20alkyl, carboxamido,
 benzoyl, C₁-20alkyloxy, C₁-20alkyl, C₂-20alkenyl, cyano, nitro.
 acetamide or halogen;

25 heteroaryl which is a mono or polycyclic system composed of 5-
 or 6-membered aromatic rings consisting of 1,2, 3 or 4
 heteroatoms chosen from N, O, or S and either unsubstituted or
 substituted with R or independently with hydroxyl, C₁-
 20alkyloxy, C₁-20alkyl, benzoyl, carboamide, acetamide,
 halogens, C₂-20alkenyl, cyano, nitro, or haloalkyl directly
 bonded to the aromatic carbon atoms(s);

30 C₆-14 arylC₁-20alkyl of the formula:

- 10 -



5

wherein the aromatic ring is optionally and independently substituted with R^7 and R^8 wherein R^7 and R^8 are

10

H,

CH₃,C₂H₅,

carboxamido,

C₁-C₆ alkylthio,C₁-C₆ alkylsulfinyl,C₁-C₆ alkylsulfonyl,

15

OCH₃,NH₂,CH₃NH,(CH₃)₂N,

OH,

20

NO₂,

CN,

F,

acetamido,

Cl,

OC₂H₅,

25


CF₃,

isopropyl, or

isobutyl; n equals 1-10 and the C₁-20alkyl portion is optionally substituted with R^5 ;


30

HeteroarylC₁-20alkyl of the formula:



. or

- 11 -



wherein X equals O, S, or NR; and n equals 1-10;

C₁-20alkylsulfonylC₁-20alkyl,

C₁-20alkylthioC₁-20alkyl,

C₁-20alkylsulfinylC₁-20alkyl of the formula:

$-(CH_2)_nS(O)_p-R^9$ wherein R⁹ is

CH₃,

C₂H₅,

C₃H₇,

C₄H₉,

isopropyl,

isobutyl,

sec-butyl,


t-butyl,

isopentyl,

neopentyl, or

ixohexyl; n equals 1-15 and p=0-2;

C₁-20alkyloxycarbonylC₁-20alkyl of the formula:



is:

CH₃,

C₂H₅,


C₃H₇,

C₄H₉, or


C₅H₁₁; and n equals 1-20;

CarboxylC₁-20alkyl of the formula:

- 12 -



5

C₁-20alkylcarbonylC₁-20alkyl of the formula

10


C₃-20cycloalkylC₁-20alkyl of the formula:

-(CH₂)_n-(cycloalkyl) wherein the cycloalkyl proton is a monocyclic, bicyclic, or polycyclic hydrocarbon of up to 20 carbon atoms wherein the rings are optionally substituted with R¹; and n = 1-20;

15


ArylC₁-20alkyloxycarbonylC₁-20alkyl of the formula:-

20




wherein n = 1-20;

25

HeteroarylC₁-20alkyloxycarbonylC₁-20alkyl of the formula:

30


haloC₁-20alkyl of the formula:hydroxylC₁-20alkyl of the formula:

- 13 -

-(CH₂)_nCH₂OH; n is 1-19;

halohydroxylC₁₋₂₀alkyl of the formula:

5



n = 1-18

q = 0-18

10

n + q = 0-18 and

X equals Br, Cl, F or I;


ThiosulfatoC₁₋₂₀alkyl of the formula:

-(CH₂)_nCH₂SSO₃Na; n is 1-19;

15


ArylC₁₋₂₀alkyloxyC₁₋₂₀alkyl of the formula:

20




ArylcarbonylarylC₁₋₂₀alkyl of the formula:

25





DiarylC₁₋₂₀alkyl of the formula:

30



- 14 -

TriarylC₁₋₂₀alkyl of the formula:Aryl C₂₋₂₀alkenyl of the formula:

n = 0-18

m = 0-18

m+n = 0-18

R⁴ is

H,

C₁₋₂₀alkyl,

25 C₆ aryl wherein aryl is a monocyclic system composed of 6-membered aromatic rings either unsubstituted or substituted with R wherein R is H, C₁₋₆ alkyl, arylC₁₋₂₀alkyl with the alkyl groups unsubstituted or substituted with hydroxyl, C₁₋₈alkyloxy, carboxy C₀₋₁₀alkyl, or halogen or aryl directly substituted

30 independently with amino, mono C_{1-C4} alkylamino, di C_{1-C4} alkylamino, mono C_{1-C4} alkylaminoaryl, di C_{1-C4} alkylaminoaryl, hydroxyl, haloC₁₋₂₀alkyl, carboxamido, benzoyl, C₁₋₂₀alkyloxy, C₁₋₂₀alkyl, C₂₋₂₀alkenyl, cyano, nitro, acetamide or halogen; or


- 15 -

heteroaryl;


5 R⁵ can be the same or different when x is greater than one and is;
H, or
C₁₋₁₂alkyl;

W is:

10



15



x is an integer from 1-10;

and the dashes indicate a double bond is optionally present.

20

The present invention is particularly concerned with
providing a method of treating the hyperandrogenic conditions of
androgenic alopecia, acne vulgaris, seborrhea, and female hirsutism by
topical and/or oral administration, and a method of treating all of the
above conditions as well as benign prostatic hyperplasia, prostatitis, the
25 prevention and/or treatment of prostatic carcinoma, by oral or
parenteral administration, of the novel compounds of the present
invention.

25

The present invention is thus also concerned with providing
suitable topical, oral and parenteral pharmaceutical formulations for
use in the novel methods of treatment of the present invention.

30


DETAILED DESCRIPTION OF THE INVENTION:

The present invention is concerned with novel 4-
azasteroidal amide compounds and pharmaceu- tical compositions and
formulations thereof that are useful as testosterone 5 α -reductase

- 16 -




inhibitors to treat various hyperandrogenic conditions including acne vulgaris, seborrhea, female hirsutism, male pattern baldness, benign prostatic hypertrophy, prostatitis, androgenic alopecia, and the prevention and treatment of prostatic carcinoma. Advantageously, the compounds of the invention may be used to treat scalp disorders by selectively inhibiting 5α -reductase 1 or the compounds may be used as dual inhibitors of 5α reductase 1 and 2 to treat the above disorders.

The present invention is concerned with compounds of the formula:



and the pharmaceutically acceptable salts thereof, wherein:

A is



wherein

- 17 -

R¹ is H, methyl or ethyl;

5 R² is H, or C₁₋₂₀ alkyl;

R³ is:

H,

C₁₋₂₀ alkyl,

10 C₅₋₁₄ aryl,

heteroaryl,

C₅₋₁₄ arylC₁₋₂₀alkyl,

heteroarylC₁₋₂₀alkyl,

C₁₋₂₀alkyloxyC₁₋₂₀alkyl,

15 C₁₋₂₀alkylthioC₁₋₂₀alkyl,

C₁₋₂₀alkyloxycarbonylC₁₋₂₀alkyl,

C₁₋₂₀ alkylC₆₋₁₄arylC₁₋₂₀alkyl,

carboxyC₁₋₂₀alkyl,

C₁₋₂₀ alkylcarbonylC₁₋₂₀alkyl,

C₃₋₂₀cycloalkyl,

20 C₃₋₂₀ cycloalkylC₁₋₂₀alkyl,

C₆₋₁₄ arylC₁₋₂₀alkyloxycarbonylC₁₋₂₀alkyl,

heteroarylC₁₋₂₀alkyloxycarbonylC₁₋₂₀alkyl,

haloC₁₋₂₀alkyl,

hydroxyC₁₋₂₀alkyl,

25 halohydroxyC₁₋₂₀alkyl,

thiosulfatoC₁₋₂₀alkyl,

C₆₋₁₄ arylC₁₋₂₀alkyloxyC₂₋₂₀alkynylC₁₋₂₀alkyl,

C₆₋₁₄ arylC₂₋₂₀alkynylC₁₋₂₀alkyl,

heteroarylC₂₋₂₀alkynylC₁₋₂₀alkyl,

30 diarylC₁₋₂₀alkyl,

triarylC₁₋₂₀alkyl,

C₂₋₂₀alkenyl,

C₆₋₁₄ arylcarbonylarylC₁₋₂₀alkyl,

C₂₋₂₀alkenylC₁₋₂₀alkyl,

- 18 -

C₆₋₁₄ arylC₂₋₂₀alkenyl, or
heteroarylC₂₋₂₀alkenyl;


5 R⁴ is

H,
C₁₋₂₀ alkyl,
C₅₋₁₄ aryl, or
10 heteroaryl;

R⁵ can be the same or different when x is greater than 1 and is:

15 H, or
C₁₋₂₀ alkyl;


W is



x is an integer from 1 to 25.

Compounds of the formula

25



30


and listed in Table 1 are representative of the compounds claimed in the instant invention. In a preferred embodiment, R¹ may be H or CH₃ and A may be as indicated in Table 1. Particular representative chemical names are also listed in Table 1 adjacent to the respective side chain and

specifically reflect whether the 1 position is saturated or unsaturated. Advantageously, R¹ is CH₃, A is as indicated in Table 1 and the 1 position is saturated. Unless otherwise indicated, the 17-position substituent is assumed to be in the beta configuration.

TABLE 1

Side Chain A	Compound(s):
<div> <div>(1)</div> <div> $\begin{array}{c} \text{H} \quad \text{O} \\ \quad \\ \text{N} - \text{C} - \\ \quad \\ \text{21} \quad \text{20} \end{array}$ </div> </div>	4-methyl-20(trimethylacetamido)- 5 α -4-aza-pregnan-3-one 4-methyl-20(trimethylacetamido)- 5 α -4-aza-1-pregnen-3-one
<div> <div>(2)</div> <div> $\begin{array}{c} \text{H} \quad \text{O} \\ \quad \\ \text{N} - \text{C} - \\ \quad \\ \text{---} \quad \text{---} \end{array}$ </div> </div>	4-methyl-17 β (trimethylacetamidomethyl)-4-aza 5 α -androst-1-en-3-one 4-methyl-17 β (trimethylacetamidomethyl)-4-aza 5 α -androstan-3-one
<div> <div>(3)</div> <div> $\begin{array}{c} \text{H} \quad \text{O} \\ \quad \\ \text{N} - \text{C} - \\ \quad \\ \text{---} \quad \text{---} \end{array}$ </div> </div>	4-methyl-17 β (trimethylacetamido)-4-aza 5 α -androst-1-en-3-one 4-methyl-17 β (trimethylacetamido)-4-aza 5 α -androstan-3-one
<div> <div>(4)</div> <div> $\begin{array}{c} \text{O} \\ \\ \text{HN} - \text{C} - \text{CH}_3 \\ \quad \\ \text{---} \quad \text{---} \end{array}$ </div> </div>	17 β (acetamido)-4-methyl-4-aza 5 α -androst-1-en-3-one 17 β (acetamido)-4-methyl-4-aza 5 α -androstan-3-one

- 20 -




4-methyl-17β(2-thiophenesulfonamidomethyl)-

4-aza-5α-androst-1-en-3-one

4-methyl-17β(2-thiophenesulfonamidomethyl)-

4-aza-5α-androstan-3-one





17βisopropylthiododecanoylamidomethyl)-

4-methyl-4-aza-5α-androst-1-en-3-one

17β(isopropylthiododecanoylamidomethyl)-

4-methyl-4-aza-5α-androstan-3-one



4-methyl-17β(2-(thiophenecarboxamido-
methyl)-4-aza-5α-androst-1-en-3-one4-methyl-17β(thiophenecarboxamido-
methyl)-4-aza-5α-androstan-3-one

17β(carbomethoxyoctanoylamidomethyl)-

4-methyl-4-aza-5α-androst-1-en-3-one

17β(carbomethoxyoctanoylamidomethyl)-

4-methyl-4-aza-5α-androstan-3-one

17β((2-(4-isobutylphenyl)-
propionamidomethyl)-4-methyl-4-aza-
5α-androst-1-en-3-one17β((2-(4-isobutylphenyl)-
propionamidomethyl)-4-methyl-4-aza-
5α-androstan-3-one






17β(8-carboxyoctanoylamidomethyl)-

4-methyl-4-aza-5α-androst-1-en-3-one





17β(8-carboxyoctanoylamidomethyl)-

4-methyl-4-aza-5α-androstan-3-one

- 21 -




- 22 -

- 5 (16)  17β(3,4-dimethoxyphenylacetamido-
methyl)-4-methyl-4-aza-5α-androstan-
3-one
- 10 (17)  17β(8-(carbomethoxy)octanoylamido)-
4-methyl-4-aza-5α-androst-1-en-3-one
17β(8-(carbomethoxy)octanoylamido)-
4-methyl-4-aza-5α-androstan-3-one
- 15 (18)  17β(12-isopropylthio)dodecanoylamido)-
4-methyl-4-aza-5α-androst-1-en-3-one
17β(12-isopropylthio)dodecanoylamido)-
4-methyl-4-aza-5α-androstan-3-one
- 20 (19)  17β(benzenesulfonamidomethyl)-4-methyl-
4-aza-5α-androst-1-en-3-one
17β(benzenesulfonamidomethyl)-4-methyl-
4-aza-5α-androstan-3-one
- 25
- 30


- 23 -

5



17β(6-Bromohexanoylamidomethyl)-
4-methyl-4-aza-5α-androst-1-en-3-one
17β(6-Bromohexanoylamidomethyl)-
4-methyl-4-aza-5α-androstan-3-one


10



17β(12-hydroxydodecanoylamidomethyl)-
4-methyl-4-aza-5α-androst-1-en-3-one

17β(12-hydroxydodecanoylamidomethyl)-
4-methyl-4-aza-5α-androstan-3-one


15



4-methyl-17β(2-(4-nitrophenyl)propionamido-
methyl)-4-aza-5α-androst-1-en-3-one

20

4-methyl-17β(2-(4-nitrophenyl)propionamido-
methyl)-4-aza-5α-androstan-3-one








17β(isopropylthioacetamidomethyl)-
4-methyl-4-aza-5α-androst-1-en-3-one

25

17β(isopropylthioacetamidomethyl)-
4-methyl-4-aza-5α-androstan-3-one

30

- 24 -

- 5 (24)  4-methyl-17 β -(6-thiosulfato)hexanoyl-amidomethyl)-4-aza-5 α -androstan-3-one
- 10 (25)  4-methyl-17 β -(benzoyloxyacetamidomethyl)-4-aza-5 α -androstan-3-one
17 β -(benzoyloxyacetamidomethyl)-4-methyl-4-aza-5 α -androstan-1-en-3-one
- 15 (26)  17 β -(carbomethoxyacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one
17 β -(carbomethoxyacetamidomethyl)-4-methyl-4-aza-5 α -androstan-1-en-3-one
- 20 (27)  17 β -(diphenylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one
17 β -(diphenylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-1-en-3-one
- 25 (28)  4-methyl-17 β -(3,3,3-triphenylpropion-amidomethyl)-4-aza-5 α -androstan-3-one
4-methyl-17 β -(3,3,3-triphenylpropion-amidomethyl)-4-aza-5 α -androstan-1-en-3-one
- 30

- 25 -

The following additional compounds may also be prepared according to the procedures described in the instant specification.

Unless otherwise specified herein, the 17-substituent is presumed to be in the beta configuration.

- 5
- 17 β -(2-Furylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
17 β -(4-Isopropylphenylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 10
- 17 β -(Cyclohexylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
17 β -(3-Indolylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
4-Methyl-17 β -(4-methylcyclohexanecarboxamidomethyl)-4-aza-5 α -androstan-3-one;
17 β -(4-(3-Indolyl)-butyramidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 15
- 17 β -(4-Isobutylbenzamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
17 β -(Acetoxyacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
17 β -(6-Bromohexanoylamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 20
- 4-Methyl-20-(4-nitrobenzamidomethyl)-4-aza-5 α -pregnan-3-one;
20-((3-Acetamido)benzamido)-4-methyl-4-aza-5 α -pregnan-3-one;
20-(3,4-Dimethoxyphenylacetamidomethyl)-4-methyl-4-aza-5 α -pregnan-3-one;
17 β -(4-Ethoxybenzamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
4-Methyl-20-(palmitoylamidomethyl)-4-aza-5 α -pregnan-3-one;
- 25
- 17 β -(Iminodibenzyl-5-carboxamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
4-Methyl-20-(stearoylamido)-4-aza-5 α -pregnan-3-one; 4-Methyl-17 β -(3,5-bis-(trifluoromethyl)benzamidomethyl)-4-aza-5 α -androstan-3-one;
17 β -(3-Cyanobenzamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 30
- 20-(Heptafluorobutyramidomethyl)-4-Methyl-4-aza-5 α -pregnan-3-one;
20-(4-Benzoylbenzamidomethyl)-4-methyl-4-aza-5 α -pregnan-3-one;
17 β -(Benzotriazol-5-carboxamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
20-(3,5-Difluorobenzamido)-4-methyl-4-aza-5 α -pregnan-3-one;

- 26 -

- 17B-(Bis-(4-isopropyl)phenyl)acetamidomethyl-4-methyl-4-aza-5 α -androstane-3-one;
- 4-Methyl-20-(Salicylamidomethyl)-4-aza-5 α -pregnan-3-one;
- 5 17B-(Cinnamoylamidomethyl)-4-methyl-4-aza-5 α -androstane-3-one;
- 17B-((3-Hydroxy-4,4,4-trichlorobutyramido)methyl)-4-methyl-4-aza-5 α -androstane-3-one;
- 17-Benzoylamido-5- α -4-methyl-4-azaandrostane-3-one;
- 17-(2-Thiophenesulfonamido)-5- α -4-methyl-4-azaandrostane-3-one;
- 10 4-Methyl-17-(phenylthioacetamido)-5- α -4-methyl-4-azaandrostane-3-one;
- 4-Methyl-17-(4-methylpentanoylamido)-5- α -4-azaandrostane-3-one;
- 4-Methyl-17-(3-thenoylamino)-5- α -4-azaandrostane-3-one;
- 17-(3-(4'-Fluoro-3,5,3'-trimethylbiphen-2-yl)propionamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 15 17-(6-(Diethylphosphono)hexanoylamino)-4-methyl-5- α -4-azaandrostane-3-one;
- 17-((t-Butylthio)acetamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 4-Methyl-17-(3-thiophenacetamido)-5- α -4-azaandrostane-3-one;
- 4-Methyl-17-(4-nitrobenzamido)-5- α -4-azaandrostane-3-one;
- 20 4-Methyl-17-(3-nitrobenzamido)-5- α -4-azaandrostane-3-one;
- 17-(2-Fluorobenzamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 17-(4-cyanobenzamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 17-(Benzthiophen-3-ylacetamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 4-Methyl-17-(2-thiophenecarboxamido)-5- α -4-azaandrostane-3-one;
- 25 17-(1-Methyl-2-pyrrolicarboxamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 17-(4-Carboxy-4-methylpentanoylamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 17-(4-Carbomethoxy-4-methylpentanoylamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 30 17-(4-Carbomethoxy-3,3-dimethylbutyroylamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 4-Methyl-17-(3-phenylbutyroylamido)-5- α -4-azaandrostane-3-one;
- 17-(2,3-Difluorobenzoylamido)-4-methyl-5- α -4-azaandrostane-3-one;
- 4-Methyl-17-(2-methylbenzoylamido)-5- α -4-azaandrostane-3-one;

- 17-(2,3-Dimethylbenzamido)-4-methyl-5- α -4-azaandrostan-3-one;
17-Cinnamoylamido-4-methyl-5- α -4-azaandrostan-3-one;
17-(3,3-Dimethylacrylamido)-4-methyl-5- α -4-azaandrostan-3-one;
5 17-(3,4-Dimethoxybenzamido)-4-methyl-5- α -4-azaandrostan-3-one;
17-(Acetoxylacetamido)-4-methyl-5- α -4-azaandrostan-3-one;
4-Methyl-17-(4-(2-nitrophenoxy)-butyroylamido)-5- α -4-azaandrostan-3-one;
17-Isobutyroylamido-4-methyl-5- α -4-azaandrostan-3-one;
10 17-(3,3-Dimethyl-4-(1-(4-isobutylphenyl)ethoxy)benzamido)-4-methyl-5- α -4-azaandrostan-3-one;
17-(4-Benzoyloxybenzamido)-methyl-5- α -4-azaandrostan-3-one;
4-Methyl-17-(3-fluoro-2-methylbenzamido)-5- α -4-azaandrostan-3-one;
4-Methyl-17-(3,5,5-trimethylhexanoylamino)-5- α -4-azaandrostan-3-one;
15 17-((Benzylthio)acetamido)-4-methyl-5- α -4-azaandrostan-3-one;
17-(2-Acetoxyisobutyramido)-4-methyl-5- α -4-azaandrostan-3-one;
4-Methyl-17-trifluoroacetamido-5- α -4-azaandrostan-3-one;
17-(2-Hydroxyisobutyramido)-4-methyl-5- α -4-azaandrostan-3-one;
17-(Isonicotinoylamino)-4-methyl-5- α -4-azaandrostan-3-one;
20 17-(t-Butylacetamido)-4-methyl-5- α -4-azaandrostan-3-one;
4-Methyl-17-phenylacetamido-5- α -4-azaandrostan-3-one;
4-Methyl-17-(picolinoylamido)-5- α -4-azaandrostan-3-one;
4-Methyl-17-(nicotinoylamido)-5- α -4-azaandrostan-3-one;
17-(3-((3-Benzamido)phenyl)propionamido)-4-methyl-5- α -4-azaandrostan-3-one;
25 17-Formamido-4-methyl-5- α -4-azaandrostan-3-one;
17-(2-(Carbomethoxy)-1-cyclopentenylcarboxamido)-4-methyl-5- α -4-azaandrostan-3-one;
17-(2,6-Difluorobenzamido)-4-methyl-5- α -4-azaandrostan-3-one;
30 17-(2,6-Dichlorobenzamidomethyl)-5- α -4-methyl-4-azaandrostan-3-one;
17-(3-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-azaandrostan-3-one;
17-(4-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-azaandrostan-3-one;
17-(3,3-Diphenylpropionamidomethyl)-5- α -4-methyl-4-azaandrostan-3-one;

- 28 -

- 17-((3-(Iminodibenz-5-ylmethyl)benzoyl)aminomethyl)-4-methyl-5- α -4-azaandrostan-3-one;
17-(3-Hydroxy-4,4,4-trichlorobutyroylamidomethyl)-5- α -4-methyl-4-azaandrostan-3-one;
5 17-Formamidomethyl-5- α -4-methyl-4-azaandrostan-3-one;
4-Methyl-17-(3,3,3-triphenylpropionamidomethyl)-5- α -4-azaandrostan-3-one;
20-((Isopropylthio)acetamido)-4-methyl-5- α -4-azapregnan-3-one;
20-((Isopropylthio)acetamido)-5- α -4-azapregnan-3-one;
10 4-Methyl-17-((phenylthio)acetamidomethyl)-5- α -4-azaandrostan-3-one;
17-((t-Butylthio)acetamidomethyl)-5- α -4-methyl-4-azaandrostan-3-one;
17-(3-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-azaandrostan-3-one;
17-(5-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-azaandrostan-3-one;
15 4-Methyl-17-(3-(trifluoromethyl)-benzamidomethyl)-5- α -4-azaandrostan-3-one;
17-Benzamidomethyl-4-methyl-5- α -4-azaandrostan-3-one or
17-(2,3-Difluorobenzamido)-4,7-dimethyl-5- α -4-azaandrostan-3-one.


- 20 Also included herein are the 4-N-H (or 4-N-CH₃ if the 4-N-H is specified) analogs of the above specified compounds.

Synthesis of Testosterone 5- α Reductase Inhibitors:

- 25 Scheme 1 illustrates the synthesis of the intermediate oximes and amines used to produce compounds claimed in the instant invention.

30

- 29 -




SCHEME 1

A stirred mixture of 4-methyl-3-oxo-5-α-4-azaandrostan-17-carboxaldehyde, hydroxylamine hydrochloride, anhydrous pyridine, and anhydrous ethanol is refluxed gently under a nitrogen atmosphere for six to seven hours. After cooling, the ice-cooled mixture is diluted, with stirring, with a slight excess of chilled dilute hydrochloric acid. The suspension is then aged for about twenty minutes, filtered, washed with water and dried to give compound 1.


A mixture of the oxime (1), ethanol, glacial acetic acid and water is reduced in the presence of platinum oxide (PtO₂) until chromatographic analysis (TLC) indicates complete reduction to the amine (2). The filtered reaction mixture is concentrated in vacuo; the resultant residue is dissolved in chloroform (CHCl₃) and washed with fresh dilute sodium hydrogen carbonate solution.

The chloroform phase is then dried with sodium sulfate (Na_2SO_4). Concentration of the resultant CHCl_3 solution followed by trituration of the residue with hexane/ether will yield 2 as a white solid.


The following amines are representative of those obtained from the corresponding carbonyl compounds utilizing the basic procedures described in Scheme 1 for preparation of the oximes and amines:



17-Aminomethyl-5- α -4-azaandrostane-3-one;



17-Amino-4-methyl-5- α -4-azaandrostane-3-one;




17-Amino-5- α -4-azaandrostane-3-one:

- 31 -

6)

5




10

20-Amino-4-methyl-5- α -4-azapregnan-3-one;

7)


15

20-Amino-5- α -4-azapregnan-3-one;

20


8)

25

20-(Aminomethyl)-4-methyl-5- α -4-azapregnan-3-one;

30


9)



20-(Aminomethyl)-5- α -4-azapregnan-3-one;

As Scheme 1 indicates, the oximes useful as intermediates may readily be prepared by reacting a 4-azasteroidal aldehyde or ketone with hydroxylamine hydrochloride to form the corresponding oxime. The resultant oximes are subsequently reduced with hydrogen (H_2) and platinum oxide (PtO_2) or other suitable reducing agent to yield the respective amine. The product amides may be further alkylated with, for example, alkyl halides to give the corresponding R^2 alkylated compounds. Alternatively, the primary amines may be alkylated by well known synthetic procedures to the corresponding secondary amines and then acylated to the product amides.

Scheme 2 illustrates the synthesis of the compound 4-methyl-17(trimethylacetyl-amido)-5- α -4-azaandrostan-3-one and is representative of a basic synthesis of compounds claimed in the instant invention in which an amine is reacted with an acylating agent (or acid equivalent). These reagents include acyl halides and acid anhydrides.


SCHEME 2

To a stirred, ice-cold solution of IV, anhydrous methylene chloride and pyridine is added trimethylacetylchloride dropwise over approximately one minute under a nitrogen atmosphere. After an additional fifteen minutes at ice-bath temperatures, the mixture is allowed to warm to room temperature ($25^\circ C$) and stirred for an additional fourteen hours. The mixture is then transferred to a separatory funnel with additional CH_2Cl_2 , washed with dilute (0.3N)

- 33 -

HCl, dried (Na_2SO_4), concentrated and recrystallized (ethyl acetate) to yield 10 as a white solid.

As Scheme 2 illustrates, 4-azasteroidal primary or
 5 secondary amines described in the instant invention are reacted with the desired activated carbonyl compound, such as trimethylacetyl chloride, to yield the target amide. Representative acyl halides or acid anhydrides of the formula:



R^3 may generally be:

15 C_{1-20} alkyl,
 aryl,
 heteroaryl,
 aryl C_{1-20} alkyl,
 heteroaryl C_{1-20} alkyl,
 C_{1-20} alkylaryl C_{1-20} alkyl,
 20 C_{1-20} alkyloxycarbonylalkyl,
 C_{1-20} alkylcarbonyl C_{1-20} alkyl,
 C_{1-20} cycloalkyl C_{1-20} alkyl,
 aryl C_{1-20} alkyloxycarbonyl C_{1-20} alkyl,
 halo C_{1-20} alkyl,
 25 aryl C_{1-20} alkyloxy C_{1-20} alkyl,
 diaryl C_{1-20} alkyl,
 triaryl C_{1-20} alkyl,
 C_{2-20} alkenyl,
 C_{2-20} alkenyl C_{1-20} alkyl,
 30 C_{2-20} alkynyl C_{1-20} alkyl,
 aryl C_{2-20} alkynyl C_{1-20} alkyl,
 heteroaryl C_{2-20} alkynyl C_{1-20} alkyl,
 or aryl C_{2-20} alkenyl may be used in the instant invention.


R^3 is also as specifically described in the examples section of the present application. R^3 may be, for example, t-butyl; 2,2-diphenylethyl, 3-thienyl, 2-thienyl, -11-(isopropylthio)undecyl, -7-
5 (carbomethoxy)heptyl, 1-(1-(4-isobutylphenyl)-ethyl, -7-(carboxy)heptyl, -acetylmethyl, -1-adamantylmethyl, -2-thienylmethyl, -2-(carbobenzyloxy)ethyl, -3,4-dimethoxyphenyl, -phenyl, -5-bromopentyl, phenylthiomethyl, -t-butylthiomethyl, -3-methyl-2-thienyl, 5-methyl-2-thienyl, -11-hydroxyundecyl, -1-(4-
10 nitrophenyl)ethyl, -isopropylthiomethyl, 5-(thiosulfato)pentyl, -benzyloxymethyl, carbomethoxymethyl, diphenylmethyl, triphenylmethyl, -2-furyl, 4-isopropylphenyl, cyclohexylmethyl, 4-methylcyclohexyl, 3-(3-indolyl)propyl, 3-Indolylmethyl, 4-isobutylphenyl, 4-nitrophenyl, 3-nitrophenyl, 3-acetamidomethyl, 4-ethoxyphenyl, hexadecyl, stearyl,
15 3,5-Bis(trifluoromethyl)benzyl, 3-cyanophenyl, heptafluoropropyl, 4-benzoylphenyl, 5-benzotriazolyl, 3,5-difourophenyl, bis(4-isopropylphenyl)methyl, 2-hydroxyphenyl, phenylvinyl, 2-hydroxy-3,3,3-trichloropropyl, methyl, allyl, n-propyl, n-octyl, isopropyl, (isopropylthio)methyl,
20 isobutyl, ethyl; 2,2,2-triphenylethyl, benzyl, octadecyl, 2(ethyl)phenyl, 3(chloro)phenyl, 4(methyl)phenyl, 2,3(dichloro)phenyl, 2,6(dichloro)phenyl, 4(fluoro)phenyl, 3(methoxy)phenyl, 3-(acetamido)phenyl, 3-(Iminodibenz-5-ylmethyl)phenyl, 3-trifluoromethylphenyl,
25 2(ethoxy)phenyl, formyl, 2-napthyl, or 2-thiazolyl. Each of the acid chlorides having the above R^3 groups are readily available from, for example, Aldrich Chemical Company or may readily be prepared from the corresponding acid.

Acyl halides or activated carbonyl compounds disclosed in
30 this invention are commercially available or may be prepared from the corresponding carboxylic acid and thionyl chloride (SOCl_2), phosphorous pentahalide (PX_5), or phosphorous trihalide (PX_3). See Ansell in Patai, "The Chemistry of Acyl Halides", 35-48, Interscience, New York (1972).

- 35 -


The primary or secondary amines disclosed in the instant invention may also be reacted with alkyl and aryl sulfonyl halides or anhydrides to yield compounds claimed in the instant invention.

If a sulfonylhalide or anhydride of the formula




is used, R^3 may equal the groups defined above for the carbonyl species.

Amides or sulfonamides representative of those obtained from the corresponding amines utilizing the basic procedure described in Scheme 2 by substituting either the amine or the activated carbonyl compound may be prepared. For example, compound 6 may be substituted for compound 4 in Scheme 2 and reacted with the indicated acylating agent (trimethylacetyl chloride) to yield compound 11 (4-methyl-20-(trimethylacetamido)-5- α -4-azapregnan-3-one). If compound 2 is reacted with 8-(carbomethoxy)octanoyl chloride using the procedure described in Scheme 2, (17-(8-(Carbomethoxy)-octanoylamidomethyl)-4-methyl-5- α -4-aza-androstan-3-one) is produced:




- 36 -

If a sulfonyl halide, for example, thiophene-2-sulfonylchloride, is substituted for an acyl halide and reacted with an amine such as 2, (4-methyl-17-(2-thiophenesulfonylamidomethyl)-5- α -4-azaandrostan-4-one) may be prepared:



Scheme 3 illustrates the synthesis of 17 β -(12-(Isopropylthio)dodecanoylamidomethyl)-4-methyl-5 α -androstan-3-one (14):

- 37 -



(* prepared from 12-bromododecanoic acid and sodium isopropylthiolate)

SCHEME 3

DCC is a well known coupling reagent used in peptide synthesis to generate amide bonds from a free acid and an amine. Coupling reagents

- 38 -

may generally be used when the free acid is readily available or when the alternative acid halide is internally labile (e.g., when a thio group is present). An intermediate anhydride of the acid is generated which
5 futher reacts with the amine. In Scheme 3, 12-(isopropylthio)-dodecanoic acid is reacted with 2, DCC, and DMAP to produce the corresponding amide (14). For example, DCC is used when R^3 is C_{1-20} alkylthio C_{1-20} alkyl or hydroxyl C_{1-20} alkyl.

Additionally, dehydrogenation of the 1,2 position or the 5,6
10 position may readily be accomplished by known synthetic methodology to produce the claimed 1-en or 5-en derivatives. See U.S. 5,061,802; Dolling et al., JACS, 110, 3318-19 (1988).

Schemes 4, 5 and 6 further illustrate how compounds
claimed in the instant invention may be prepared. In Scheme 4, the
15 staring 4-azasteroid aldehyde or ketone (XV), obtained by known synthetic methods, is reacted to form the oxime (XVI); reduced to the amine (XVII) and reacted with an activated carbonyl or sulfonyl compound and, optionally, an alkylhalide ($X-R^2$) to form XVIII. Of


20

25

30

- 39 -

course, if the optional alkyl halide is not utilized, R^2 on XVIII is H.

Scheme 4


In Scheme 5, the identical procedure is followed using a generic 4-azasteroid (XIX) prepared by known synthetic methods to produce the oxime (XX) which is reduced to the amine (XXI) and reacted with an

25

30

- 40 -


activated carbonyl or sulfonyl compound ($X-W-R^3$) to yield (XXII).



Scheme 5


In Scheme 6, the generic 4-azasteroid XXIII, also obtained from well known synthetic methodology, is reacted to form the oxime XXIV which is further reduced to form XXV and subsequently reacted with an activated carbonyl or sulfonyl compound to form XXVI.

- 41 -


SCHEME 6

The starting 4-azasteroidal ketones used in the present invention may be prepared according to the well known basic procedures described in Scheme 7.

- 42 -



- 43 -



* U. S. Pat. No. 4,377,584

Scheme 7

The following examples further describe the synthesis of compounds claimed in the instant invention.

Synthesis of Starting -4-azasteroid oximes:EXAMPLE 1

1) 4-Methyl-3-oxo-5- α -4-azaandrostan-17-carboxaldehyde oxime

A stirred mixture of 4-methyl-3-oxo-5- α -4-azaandrostan-17-carboxaldehyde (0.952 g, 3.0 mM), hydroxylamine hydrochloride (1.10 g, 15.8 mM), anhydrous pyridine (6 mL), and anhydrous ethanol (12 mL) was refluxed gently under a nitrogen atmosphere for 6.3 hours. After cooling, the ice-cooled mixture was diluted, with stirring, with a slight excess of chilled dilute hydrochloric acid (ca. 0.3 N), the suspension was aged for ca. 20 minutes, filtered,

- 44 -

washed with water and dried to give (1) 0.855 g. MS M^+ calcd for $C_{20}H_{32}H_2O_2$ 332.48. observed m/e 332.

5 Synthesis of Reactant 4-azasteroid Amines:

EXAMPLES 2-9

2) 17-Aminomethyl-4-methyl-5- α -4-azaandrostan-3-one.

10

A mixture of (1) (0.67 g., 2.0 mM), ethanol (100 mL), glacial acetic acid (8 mL) and water (4 mL) was reduced in a hydrogen atmosphere (40 p.s.i.) at room temperature in the presence of PtO_2 until TLC analysis indicated complete reduction. The filtered reaction mixture was concentrated in vacuo, the residue taken up in chloroform, and the chloroform solution washed with fresh dilute sodium hydrogen carbonate solution and dried (Na_2SO_4). Concentration of the filtered chloroform solution followed by trituration of the residue obtained with hexane containing a small amount of ether yielded

15

20

(2) as an off-white solid. MS MH^+ calcd for $C_{20}H_{34}N_2O$ 318.49, observed m/e 319.

The following amines are representative of those obtained from the corresponding carbonyl compounds utilizing the above procedures:

25

3) 17-Aminomethyl-5- α -4-azaandrostan-3-one.

4) 17-Amino-4-methyl-5- α -4-azaandrostan-3-one.

30

5) 17-Amino-5- α -4-azaandrostan-3-one.

6) 20-Amino-4-methyl-5- α -4-azapregnan-3-one.

7) 20-Amino-5- α -4-azapregnan-3-one.

8) 20-(Aminomethyl)-4-methyl-5- α -4-azapregnan-3-one.

5 9) 20-(Aminomethyl)-5- α -4-azapregnan-3-one.

Synthesis of Amino substituted azasteroids:

EXAMPLES 10-14

10 10) 4-Methyl-17B-(trimethylacetamido)-5- α -4-azaandro-
stan-3-one.

15 To a stirred, ice-cold solution of (4) (0.091 g, 0.3 mM),
anhydrous methylene chloride (5 mL), and pyridine (0.1 mL, 1.2 mM),
was added trimethylacetyl chloride (0.05 mL, 0.4 mm) dropwise over
ca. one minute (nitrogen atmosphere). After an additional 15 min. at
ice-bath temperatures the mixture was allowed to warm to room
temperature and stir at ambient temperature overnight. The mixture
20 was then transferred to a separatory funnel with additional methylene
chloride, washed with dilute (ca. 0.3N) hydrochloric acid, and dried
(Na₂SO₄). Concentration of the filtered solution followed by
recrystallization (ethyl acetate) of the residue obtained gave (10) as a
white solid. MS M⁺ calcd for C₂₄H₄₀N₂O₂ 388.59, observed m/e 388.

25 11) 4-Methyl-20-(trimethylacetamido)-5- α -4-azapreg-
nan-3-one.

30 When (4) in the above reaction was replaced by (6), (11)
was obtained as a white solid. MS M⁺ calcd for C₂₆H₄₄H₂O₂ 416.65,
observed m/e 416.

12) 17B-(8-(Carbomethoxy)octanoylamidomethyl)-4-
methyl-5- α -4-azaandrostan-3-one.

- 46 -

When (2) was reacted with 8-carbomethoxy-octanoyl chloride using the conditions of Example (10), (12) was obtained as a thick oil. MS M^+ calcd for $C_{30}H_{50}N_2O_4$ 502.74, observed m/e 502.

13) 4-Methyl-17 β -(2-thiophenesulfonylamidomethyl)-5- α -4-azaandrostan-3-one.

When the 8-carbomethoxyoctanoyl chloride in the above example was replaced with 2-thiophene-sulfonyl chloride, (13) was obtained as a white solid. MS M^+ calcd for $C_{24}H_{36}N_2O_3S_2$ 464.68, observed m/e 464.

14) 17 β -(12-(Isopropylthio)dodecanoylamidomethyl)-4-methyl-5- α -4-aza-androstan-3-one.

To a stirred solution of (2) (0.028 g, 0.09 mM) and 12-(isopropylthio)dodecanoic acid (0.025 g, 0.09 mM) (prepared from 12-bromododecanoic acid and sodium isopropylthiolate by heating in 1,2-dimeth-oxyethane) in methylene chloride (3 mL) was added 4-(dimethylamino)-pyridine (0.011 g, 0.09 mM) followed by a solution of N,N'-dicyclohexylcarbodiimide (0.020 g, 0.097 mM) in a minimum of the same solvent. After stirring for 12-14 hours, the mixture was filtered and the filtrate concentrated in vacuo. Flash chromatography (silica gel, ethyl acetate as eluant) yielded (14) as a very thick oil. MS MH^+ calcd for $C_{35}H_{62}N_2O_2S$ 574.95, observed m/e 575.

Examples 15-38 in the following list are prepared according to the basic procedures described above to further exemplify the invention.

15) 4-Methyl-17 β (trimethylacetamidomethyl)-4-aza-5 α -androstan-3-one;

16) 17 β (Acetamido)-4-methyl-4-aza-5 α -androstan-3-one;

- 17) 4-Methyl-17 β (2-thiophenecarboxamidomethyl)-4-aza-5 α -androstan-3-one;
- 18) 17 β (2-(4-Isobutylphenyl)propionamidomethyl)-
5 4-methyl-4-aza-5 α -androstan-3-one;
- 19) 17 β (8-Carboxyoctanoylamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 20) 17 β (Acetoacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 10 21) 17 β (1-Adamantylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 22) 4-Methyl-17 β (2-thiopheneacetamidomethyl)-4-aza-5 α -androstan-3-one;
- 23) 17 β (12-(t-Butylthio)dodecanoylamido)-4-methyl-4-aza-5 α -androstan-3-one;
- 15 24) 17 β (3-(Carbobenzyloxy)propionamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 25) 17 β (3,4-Dimethoxyphenylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 20 26) 17 β (8-(Carbomethoxy)octanoylamido)-4-methyl-4-aza-5 α -androstan-3-one;
- 27) 17 β (Isopropylthiododecanoylamido)-4-methyl-4-aza-5 α -androstan-3-one;
- 28) 17 β (Benzenesulfonamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 25 29) 17 β (6-Bromohexanoxylamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 30) 17 β (12-Hydroxydodecanoylamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 31) 4-Methyl-17 β (2-(4-nitrophenyl)propionamido-methyl)-4-aza-5 α -androstan-3-one,
- 30 32) 17 β (Isopropylthioacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one;
- 33) 4-Methyl-17 β (6-(thiosulfato)hexanoylamidomethyl)-4-aza-5 α -androstan-3-one;

- 48 -

- 34) 17 β -(Benzyloxyacetamidomethyl)-4-methyl-4-
aza-5 α -androstan-3-one;
- 5 35) 17 β -(Carbomethoxyacetamidomethyl)-4-methyl-4-aza-5 α -
androstan-3-one;
- 36) 17 β -(Diphenylacetamidomethyl)-4-methyl-4-
aza-5 α -androstan-3-one;
- 37) 4-Methyl-17 β -(3,3,3-triphenylpropion
amidomethyl)-4-aza-5 α -androstan-3-one;
- 10 38) 4-Methyl-17 β -(3-thiophenecarboxamido)-4-aza-
5 α -androstan-3-one.

In addition to the above compounds, the following compounds were also
prepared according to the basic procedures described in the
specification:

15

39) 17-(2,6-Dichlorobenzamidomethyl)-5- α -4-methyl-4-
azaandrostan-3-one.

40) 17-(3-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-
azaandrostan-3-one.

20

41) 17-(4-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-
azaandrostan-3-one.

42) 17-(3,3-Diphenylpropionamidomethyl)-5- α -4-methyl-4-
azaandrostan-3-one.

25

43) 17-Benzoylamido-5- α -4-methyl-4-azaandrostan-3-one.

44) 17-(2-Thiophenesulfonamido)-5- α -4-methyl-4-
azaandrostan-3-one.

30

45) 17-((3-(Iminodibenz-5-ylmethyl)benzoyl)aminomethyl)-4-
methyl-5- α -4-azaandrostan-3-one.

46) 17-(3-Hydroxy-4,4,4-trichlorobutyroylamidomethyl)-5-
 α -4-methyl-4-azaandrostan-3-one.

- 49 -

- 47) 17-Formamidomethyl-5- α -4-methyl-4-azaandrostan-3-one.
- 48) 4-Methyl-17-(3,3,3-triphenylpropionamidomethyl)-5- α -4-
5 azaandrostan-3-one.
- 49) 4-Methyl-17-(phenylthioacetamido)-5- α -4-methyl-4-
azaandrostan-3-one.
- 50) 4-Methyl-17-(4-methylpentanoylamido)-5- α -4-
10 azaandrostan-3-one.
- 51) 20-((Isopropylthio)acetamido)-4-methyl-5- α -4-azapregnan-
3-one.
- 52) 20-((Isopropylthio)acetamido)-5- α -4-azapregnan-3-one.
- 53) 4-Methyl-17-(3-thenoylamino)-5- α -4-azaandrostan-3-one.
15
- 54) 4-Methyl-17-((phenylthio)acetamidomethyl)-5- α -4-
azaandrostan-3-one.
- 55) 17-(3-(4'-Fluoro-3,5,3'-trimethylbiphen-2-
20 yl)propionamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 56) 17-(6-(Diethylphosphono)hexanoylamino)-4-methyl-5- α -4-
azaandrostan-3-one.
- 57) 17-((t-Butylthio)acetamidomethyl)-5- α -4-methyl-4-
25 azaandrostan-3-one.
- 58) 17-(3-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-
azaandrostan-3-one.
- 59) 17-((t-Butylthio)acetamido)-4-methyl-5- α -4-azaandrostan-
30 3-one.
- 60) 17-(5-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-
azaandrostan-3-one.

- 50 -

- 61) 4-Methyl-17-(3-(trifluoromethyl)-benzamidomethyl)-5- α -4-azaandrostan-3-one.
- 5 62) 17-Benzamidomethyl-4-methyl-5- α -4-azaandrostan-3-one.
- 63) 4-Methyl-17-(3-thiophenacetamido)-5- α -4-azaandrostan-3-one.
- 64) 4-Methyl-17-(4-nitrobenzamido)-5- α -4-azaandrostan-3-one.
- 10 65) 4-Methyl-17-(3-nitrobenzamido)-5- α -4-azaandrostan-3-one.
- 66) 17-(2-Fluorobenzamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 15 67) 17-(4-cyanobenzamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 68) 17-(Benzthiophen-3-ylacetamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 20 69) 4-Methyl-17-(2-thiophenecarboxamido)-5- α -4-azaandrostan-3-one.
- 70) 17-(1-Methyl-2-pyrrolicarboxamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 25 71) 17-(4-Carboxy-4-methylpentanoylamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 72) 17-(4-Carbomethoxy-4-methylpentanoylamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 30 73) 17-(4-Carbomethoxy-3,3-dimethylbutyroylamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 74) 4-Methyl-17-(3-phenylbutyroylamido)-5- α -4-azaandrostan-3-one.

- 51 -

- 75) 17-(2,3-Difluorobenzoylamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 5 76) 4-Methyl-17-(2-methylbenzoylamido)-5- α -4-azaandrostan-3-one.
- 77) 17-(2,3-Dimethylbenzamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 10 78) 17-Cinnamoylamido-4-methyl-5- α -4-azaandrostan-3-one.
- 79) 7-(3,3-Dimethylacrylamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 80) 17-(3,4-Dimethoxybenzamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 15 81) 17-(Acetoxylacetamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 82) 4-Methyl-17-(4-(2-nitrophenoxy)-butyroylamido)-5- α -4-azaandrostan-3-one.
- 20 83) 17-Isobutyroylamido-4-methyl-5- α -4-azaandrostan-3-one.
- 84) 17-(3,3-Dimethyl-4-(1-(4-isobutylphenyl)ethoxy)benzamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 25 85) 17-(4-Benzoyloxybenzamido)-methyl-5- α -4-azaandrostan-3-one.
- 86) 4-Methyl-17-(3-fluoro-2-methylbenzamido)-5- α -4-azaandrostan-3-one.
- 30 87) 4-Methyl-17-(3,5,5-trimethylhexanoylamino)-5- α -4-azaandrostan-3-one.
- 88) 17-((Benzylthio)acetamido)-4-methyl-5- α -4-azaandrostan-3-one.

- 89) 17-(2-Acetoxyisobutyramido)-4-methyl-5- α -4-azaandrostan-3-one.
- 5 90) 4-Methyl-17-trifluoroacetamido-5- α -4-azaandrostan-3-one.
- 91) 17-(2-Hydroxyisobutyramido)-4-methyl-5- α -4-azaandrostan-3-one.
- 92) 17-(Isonicotinoylamino)-4-methyl-5- α -4-azaandrostan-3-one.
- 10 93) 17-(t-Butylacetamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 94) 4-Methyl-17-phenylacetamido-5- α -4-azaandrostan-3-one.
- 15 95) 4-Methyl-17-(picolinoylamido)-5- α -4-azaandrostan-3-one.
- 96) 4-Methyl-17-(nicotinoylamido)-5- α -4-azaandrostan-3-one.
- 97) 17-(3-((3-Benzamido)phenyl)propionamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 20 98) 17-Formamido-4-methyl-5- α -4-azaandrostan-3-one.
- 99) 17-(2-(Carbomethoxy)-1-cyclopentenylcarboxamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 25 100) 17-(2,6-Difluorobenzamido)-4-methyl-5- α -4-azaandrostan-3-one.
- 101) 17-(2,3-Difluorobenzamido)-4,7-dimethyl-5- α -4-azaandrostan-3-one.

30

Table 2 illustrates the NMR data of some of the above examples.

- 53 -

TABLE 2
NMR DATA (PPM)

5	Example	Angular Methyls	Miscellaneous
	10	0.68, 0.88	1.20 (-NHCOC(CH ₃) ₃)
	11	0.72, 0.88	1.17 (-NHCOC(CH ₃) ₃)
	12	0.67, 0.89	3.66 (-CO ₂ CH ₃)
	13	0.61, 0.88	2.93 (-4-NCH ₃)
10	14	0.67, 0.89	1.24 (-SCH(CH ₃) ₂)
			1.28
	15	0.67, 0.88	1.18 (-NHCOC(CH ₃) ₃)
	16	0.70, 0.88	1.98 (-NHCOCH ₃)
	17	0.72, 0.89	2.93 (-4-NCH ₃)
15	18	0.57, 0.85	2.91 (-4-NCH ₃)
			(split)
	19	0.66, 0.88	2.92 (-4-NCH ₃)
	20	0.64, 0.88	2.24 (-COCH ₃)
	21	0.66, 0.88	2.93 (-4-NCH ₃)
20	22	0.61, 0.87	3.78 (-COCH ₂ -(C ₄ H ₃ S))
	23	0.70, 0.89	1.33 (-SC(CH ₃) ₃)
	24	0.64, 0.88	5.12 (-CO ₂ CH ₂ Ph)
	25	0.60, 0.88	3.52(d) (-Ph-(OCH ₃) ₂)
	26	0.70, 0.89	3.66 (-CO ₂ CH ₃)
25	27	0.70, 0.89	1.24 (-SCH(CH ₃) ₂)
			1.28

- 54 -

TABLE 2 (CONTD)
NMR DATA (PPM)

5	Example	Angular Methyls	Miscellaneous
	28	0.57, 0.87	2.91 (-4-NCH ₃)
	29	0.67, 0.88	2.92 (-4-NCH ₃)
10	30	0.66, 0.88	2.92 (-4-NCH ₃)
	31	0.61, 0.86	2.92 (-4-NCH ₃)
	32	0.68, 0.88	(split) 1.24 (-SCH(CH ₃) ₂)
	33	0.67, 0.89	1.28 2.93 (-4-NCH ₃)
15	34	0.65, 0.88	4.56 (-OCH ₂ Ph)
	35	0.68, 0.89	3.75 (-CO ₂ CH ₃)
	36	0.60, 0.86	4.92 (-COCH(Ph) ₂)

20 Also included with the scope of this invention are 4-N-X
analogues where X is OH, NH₂ or SCH₃. The 4-N-OH and 4-N-NH₂
derivatives can be made by incorporating hydroxylamine or hydrazine,
respectively, in place of methylamine in the seco acid ring A closure for
the starting androstanes herein as described in J. Med Chem. 29, 2298-
2315 (1986) by Rasmusson *et al.* Further, reaction of the anion of the
25 saturated 4-N-H androstanes, wherein the anion is generated from the 4-
NH precursor by sodium hydride and methylsulfonyl chloride can
produce the corresponding 4-N-5-CH₃ derivative. Thus, substituent R
on the 4-N position also includes OH, NH₂ and S-CH₃.

30 The above examples are non-limiting and suitable acylating
agents may readily be substituted according to the methods described in
the present invention and reacted with a described amine to form the
claimed amides. The following definitions further clarify the present
invention.

- 55 -

The Rf values cited were carried out on standard thin layer chromatographic Si gel plates. The elution solvent system used is given in the parentheses following the Rf value.

5 The mass spectral values are given either as FAB, i.e., fast atom bombardment, or electron impact (EI) and are reported as molecular ion peaks, being (M), (M+1) or (M+2), the molecular weight, MW, or the MW plus one or two atomic units.

10 The nuclear magnetic resonance data was taken at 200 or 400 MHz in CDCl₃ and is tabulated for unique proton values of each compound at the end of the Examples. The coupling constant J is given in Hertz, Hz.

The invention further relates to all stereoisomers, diastereomers or enantiomers of the compounds depicted.

15 The term "pharmaceutically acceptable salts" shall mean non-toxic salts of the compounds of this invention which are generally prepared by the free base with a suitable organic or inorganic acid. Representative salts include the following salts: Acetate, adipate, alginate, aspartate benzenesulfonate, benzoate, bicarbonate, bisulfate
20 borate, butyrate, camsylate, carbonate, camphorate, chloride, citrate, digluconate, fumarate, glucoheptanate, gluconate, glutamate, glycerophosphate, hydrobromide, hydrochloride, hydroiodide, lactate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate.

25 The term "pharmaceutically effective amount" shall mean that amount or quantity of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system or animal that is being sought by a researcher or clinician or physician.

30 The term "aryl" shall mean a mono- or polycyclic system composed of 6-membered aromatic rings either unsubstituted or substituted with R wherein R is defined to include H, C₁₋₆alkyl, arylC₁₋₂₀alkyl wherein the alkyl groups are unsubstituted or substituted with C₁₋₈ alkyloxy, carboxyC₀₋₁₀alkyl, hydroxy, or halogen. The term "aryl" also encompasses those aromatic systems which independently have hydroxyl, C₁₋₁₀alkyl, C₂₋₂₀alkenyl, C₁₋₂₀alkyloxy, haloC₁₋

- 56 -

20alkyl, benzoyl, cyano, nitro, carboxamide, acetamido and halogens directly bonded to the aromatic carbon atom(s) or as further defined in the specification. The term aryl clearly includes unsubstituted or substituted with R as defined above phenyl, naphthyl, anthracenyl of C₆-14 carbon atoms and/or biphenyl.

The term "heteroaryl" shall mean a mono- or polycyclic system composed of 5- and 6-membered aromatic rings containing 1,2,3 or four heteroatoms chosen from N, O, or S and either unsubstituted or substituted with R as defined above independently or with hydroxyl, C₁-20alkyloxy, C₁-20alkyl, C₂-20 alkenyl, haloC₁-20alkyl, benzoyl, cyano, nitro, carboxamide, acetamide and halogens directly bonded to the aromatic carbon atom(s). The term heteroaryl is further defined to include heterocyclic species such as 5-7-membered monocyclic rings which are either saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring so that a portion of the molecule is aromatic. Examples of heterocyclic species or elements include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, iminodibenzyl, benzimidazolyl, thiadiazolyl, thienyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl. Preferred embodiments clearly include those heteroaryl and heterocyclic species depicted in the specific examples.

- 57 -

The term "alkyl" shall mean straight or branched chain alkane.

5 The term "alkenyl" shall mean straight or branched chain alkene.

The term "alkynyl" shall mean straight or branched chain alkyne.

10 The term "cycloalkyl" shall mean cycloalkyl groups of C₃-20 carbon atoms unsubstituted or substituted with typical cycloalkyl substituents such as those shown in the specific examples herein.

The term "cycloalkenyl" shall mean cycloalkenyl groups of C₃-20 carbon atoms having one or more double bonds unsubstituted or substituted with typical cycloalkenyl substituents such as those shown in the specific examples herein.

15 The term "arylalkyl" shall be taken to include an aryl portion as defined above and an alkyl portion as defined above.

The term "heteroarylalkyl" shall mean an heteroaryl portion as defined above and an alkyl portion as defined above.

20 The "C_{1-n}" designation where n may be an integer from 1 to 20 or 3-20 respectively refers to the alkyl portion, the cycloalkyl portion or to the alkyl portion of an arylalkyl or heteroarylalkyl unit. In addition, it refers to alkenyl, aryl or alkynyl substituents.

The term "halogen" shall include fluorine, chlorine, iodine and bromine.

25 The term "oxy" shall mean an oxygen (O) atom.

The term "thio" shall mean a sulfur atom.

In the schemes and examples described in this disclosure, various reagent symbols have the following meanings:

30 PtO₂ is platinum oxide
TLC is thin layer chromatography
Na₂SO₄ is sodium sulfate
DMAP is 4-(dimethylamino)pyridine
DCC is N,N'-dicyclohexylcarbodiimide

- 58 -

The present invention has the objective of providing suitable topical, oral and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention.

5 The compositions containing the compounds of the present invention as the active ingredient for use in the treatment of e.g., benign prostatic hypertrophy, prostatitis, and treatment and prevention of prostatic carcinoma, hyperandrogenic conditions, can be administered in a wide variety of therapeutic dosage forms in
10 conventional vehicles for systemic administration, as, for example, by oral administration in the form of tablets, capsules, solutions, or suspensions, or by injection. The daily dosage of the products may be varied over a wide range varying from 0.5 to 1,000 mg per adult human/per day. The compositions are preferably provided in the
15 form of scored tablets containing 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, and 50.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.002 mg. to about 50 mg./kg. of body weight per day. Preferably the range is from about 0.01 mg. to 7 mg./kgs. of body
20 weight per day. These dosages are well below the toxic dose of the product. For the treatment of androgenic alopecia, acne vulgaris, seborrhea, female hirsutism, the compounds of the present invention are administered in a pharmaceutical composition comprising the active compound in combination with a pharmacologically acceptable
25 carrier adapted for topical, oral or parenteral administration.

These topical pharmaceutical compositions may be in the form of a cream, ointment, gel or aerosol formulation adapted for application to the skin. These topical pharmaceutical compositions containing the compounds of the present invention ordinarily include
30 about 0.1% to 15%, preferably about 5%, of the active compound, in admixture with about 95% of vehicle.

The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills,

- 59 -

powders, granules, elixers, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, all using
5 forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as a 5 α -reductase agent.

The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including
10 type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or
15 veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a
20 drug.

Oral dosages of the present invention, when used for the indicated effects, will range between about Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, preferred compounds for the
25 present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather
30 than intermittant throughout the dosage regimen.

In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as

"carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

5 For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents
10 can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium
15 oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

 The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small
20 unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

 Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the
25 compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl- methacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine
30 substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid,

polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

5

BIOLOGICAL ASSAYS

Preparation of Human prostatic and scalp 5 α -reductases.

Samples of human tissue were pulverized using a freezer mill and homogenized in 40 mM potassium phosphate, pH 6.5, 5 mM magnesium sulfate, 25 mM potassium chloride, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol (DTT) containing 0.25 M sucrose using a Potter-Elvehjem homogenizer. A crude nuclear pellet was prepared by centrifugation of the homogenate at 1,500xg for 15 min. The crude nuclear pellet was washed two times and resuspended in two volumes of buffer. Glycerol was added to the resuspended pellet to a final concentration of 20%. The enzyme suspension was frozen in aliquots at -80°C. The prostatic and scalp reductases were stable for at least 4 months when stored under these conditions.

15

5 α -reductase assay.

The reaction mixture contained in a final volume of 100 μ l is: 40 mM buffer (human scalp, potassium phosphate, pH 6.5; human prostatic 5 α -reductase, sodium citrate, pH 5.5), 0.3-10 μ M ¹⁴C-T (or ³H-T), 1 mM DTT, and 500 μ M NADPH. Typically, the assay was initiated by the addition of 50-100 μ g prostatic homogenate or 75-200 μ g scalp homogenate and incubated at 37°C. After 10-50 min the reaction was quenched by extraction with 250 μ l of a mixture of 70% cyclohexane: 30% ethyl acetate containing 10 μ g each DHT and T. The aqueous and organic layers were separated by centrifugation at 14,000 rpm in an Eppendorf microfuge. The organic layer was subjected to normal phase HPLC (10 cm Whatman partisil 5 silica column equilibrated in 1 ml/min 70 % cyclohexane: 30 % ethyl acetate; retention times DHT, 6.8-7.2 min; androstanediol, 7.6-8.0; T, 9.1-9.7 min). The HPLC system consisted of a Waters Model 680 Gradient System equipped with a Hitachi Model 655A autosampler, Applied Biosystems Model 757 variable UV detector, and a Radiomatic Model A120 radio-

25

30

- 62 -

activity analyzer. The conversion of T to DHT was monitored using the radioactivity flow detector by mixing the HPLC effluent with one volume of Flo Scint 1 (Radiomatic). Under the conditions described, the production of DHT was linear for at least 25 min. The only steroids observed with the human prostate and scalp preparations were T, DHT and androstanediol.

Stumptail macaque protocol

The following protocol is utilized with the stumptail macaque monkey to demonstrate the effect of compounds of the present invention for promoting hair growth.

Twenty-one male stumptail macaque monkeys of species *Macaca speciosa* are assigned to vehicle control and drug treatment groups on the basis of baseline hair weight data. This assignment procedure is necessary to insure that the average baseline hair growth for each control and experimental group is comparable. The control and drug treatment groups are as follows:

1. Topical 50:30:20 vehicle (N = 6)
2. Oral 5 α -reductase and topical 50:30:20 vehicle (N = 5)
3. Oral placebo (N = 5)
4. 5 α -reductase in vehicle (N = 5)

The vehicle consists of 50% propylene glycol, 30% ethanol and 20% water. A 100 mM concentration of topical 5 α -reductase is formulated in this vehicle. The same 5 α -reductase is administered as an oral dose of 0.5mg per monkey. Immediately prior to the dosing phase of the study, hair is removed from a 1 inch square area (identified by four tatoos) in the center of the balding scalp. This hair collection is the baseline hair growth determination prior to the beginning of treatment.

Approximately 250 μ L of vehicle and 5 α -reductase in vehicle is prepared and topically administered to the tatoored area of the scelp. The selected 5 α -reductase and placebo is ingested by the monekys at the same time as

- 63 -

the topical doses are administered. The monkeys are dosed once per day, seven days per week for twenty weeks.

5 At four week intervals throughout the dosing phase of the study, each monkey is shaved and the hair is collected and weighed. The body weight data (at baseline and during assay) is analyzed by the nonparametric Wilcoxon rank-sum test. Differences are significant at $p < 0.05$. Hair weight data at each week collection for vehicle, placebo and treatment groups are expressed as the change from baseline.

10 Statistical analysis is performed on the rank of the data to show overall differences among groups at each four week collection.

15 While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred dosages as set forth herein above may be applicable as a consequence of variations in the responsiveness of the mammal being treated for any of the indications for the compounds of the invention indicated above.


20 Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in

25 accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be limited only by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

30

WHAT IS CLAIMED IS:



1. A compound of the formula:




I

and the pharmaceutically acceptable salts thereof, wherein:

A is:



except when R² equals H, there is a 5 α H and W equals C(O), R³ can not be C₁₋₁₂ alkyl,



; wherein

R¹ is:

H,
methyl or ethyl;

R² is:

- 65 -

H, or
C₁-20 alkyl;

5

R³ is:

10

H,
aminoC₁-C₄alkyl,
mono C₁-C₄alkylaminoC₁-C₄alkyl,
di C₁-C₄alkylaminoC₁-C₄alkyl,
mono C₁-C₄ alkylaminoaryl,
di C₁-C₄ alkylaminoaryl,
C₁-20 alkyl,
C₆-14 aryl,
heteroaryl,
C₆-14 arylC₁-20alkyl,
heteroarylC₁-20alkyl,
C₁-20alkylthioC₁-20alkyl,
C₁-20alkylsulfinylC₁-20alkyl,
C₁-20alkylsulfonylC₁-20alkyl,
C₀-10alkylC₆-14arylthioC₁-20alkyl,
C₀-10alkylC₆-14arylsulfinylC₁-20alkyl,
C₀-10alkylC₆-14arylsulfonylC₁-20alkyl,
C₁-20alkyloxycarbonylC₁-20alkyl,

25


carboxylC₁-20alkyl,
carboC₁-20alkyloxyC₁-20alkyl,
C₁-20alkylcarbonylC₁-20alkyl,
carboxylC₁-20alkyl,

30

C₁-20alkylcarbonylC₁-20alkyl,
C₃-20cycloalkyl,
C₃-20cycloalkenyl,
C₃-20cycloalkylC₁-20alkyl,
C₆-14 arylC₁-20alkyloxycarbonylC₁-20alkyl,
heteroarylC₁-20alkyloxycarbonylC₁-20alkyl,


- 66 -

haloC₁₋₂₀alkyl,
 hydroxylC₁₋₂₀alkyl,
 iminodibenzylC₁₋₂₀alkylC₆₋₁₄aryl,
 5 halohydroxylC₁₋₂₀alkyl,
 thiosulfatoC₁₋₂₀alkyl,
 C₆₋₁₄ arylC₁₋₂₀alkyloxyC₁₋₂₀alkyl,
 C₁₋₂₀alkyloxyC₁₋₂₀alkyl,
 C₆₋₁₄ arylcarbonylC₆₋₁₄arylC₁₋₂₀alkyl,
 10 diarylC₁₋₂₀alkyl of the formula:



, n equals 0-19;

triarylC₁₋₂₀alkyl of the formula:



, n equals 1-19;

C₂₋₂₀ alkenyl,
 C₂₋₂₀ alkenylC₁₋₂₀alkyl,
 C₆₋₁₄aryloxyC₆₋₁₄aryl,
 heteroarylC₂₋₂₀alkenyl,
 30 C₆₋₁₄ arylC₂₋₂₀alkenyl,
 C₂₋₂₀alkynylC₁₋₂₀alkyl,
 C₆₋₁₄arylcarboamideC₆₋₁₄arylC₁₋₂₀alkyl,
 phosphonoC₁₋₂₀alkyl,
 C₆₋₁₄ arylC₂₋₂₀alkynylC₁₋₂₀alkyl, or

- 67 -

heteroarylC₂-20alkynylC₁-20alkyl;

R⁴ is:

- 5 H,
 C₁-20 alkyl,
 C₆ aryl wherein aryl is a monocyclic system composed of 6-
 membered aromatic rings either unsubstituted or substituted with
 R wherein R is H, C₁-6 alkyl, arylC₁-20alkyl with the alkyl
10 groups unsubstituted or substituted with hydroxyl, C₁-8alkyloxy,
 carboxy C₀-10alkyl, or halogen or aryl directly substituted
 independently with amino, mono C₁-C₄ alkylamino, di C₁-C₄
 alkylamino, mono C₁-C₄ alkylaminoaryl, di C₁-C₄
 alkylaminoaryl, hydroxyl, haloC₁-20alkyl, carboxamido,
15 benzoyl, C₁-20alkyloxy, C₁-20alkyl, C₂-20alkenyl, cyano, nitro,
 acetamide or halogen; or
 heteroaryl;

R⁵ can be the same or different when x is greater than 1 and is:

- 20 H, or
 C₁-12 alkyl;


R⁷ or R⁸ are:

- 25 H,
 CH₃,
 C₂H₅,
 carboxamido,
 C₁-6 alkylthio,
 C₁-C₆ alkylsulfinyl,
 C₁-C₆ alkylsulfonyl,
30 OCH₃,
 NH₂,
 CH₃NH,
 (CH₃)₂N,
 OH,

- 68 -

5 NO₂,
CN,
F,
acetamido,
Cl,
OC₂H₅,
CF₃,
isopropyl, or
10 isobutyl; n equals 1-10 and the C₁₋₂₀ alkyl portion is optionally substituted with R⁵;

W is:



20


x is an integer from 1-25;
and the dashes indicate a double bond is optionally present.

25

2. A compound according to Claim 1 of the formula:

30




- 69 -



I

and the pharmaceutically acceptable salts thereof, wherein:

A is:



R¹ is:

H,
methyl, or ethyl;

R² is:

H, or
C₁₋₂₀alkyl;

- 70 -

R³ is:

H,

5 C₁-20alkyl is a straight or branched chain alkane of up to 20 carbon atoms;


10 C₆-14 aryl wherein aryl is a mono or polycyclic system composed of 6-membered aromatic rings either unsubstituted or substituted with R wherein R is H, C₁-6 alkyl, arylC₁-20alkyl with the alkyl groups unsubstituted or substituted with hydroxyl, C₁-8alkyloxy, carboxy C₀-10alkyl, or halogen or aryl directly substituted independently with amino, mono C₁-C₄ alkylamino, di C₁-C₄ alkylamino, mono C₁-C₄ alkylaminoaryl, di C₁-C₄ alkylaminoaryl, hydroxyl, haloC₁-20alkyl, carboxamido, 15 benzoyl, C₁-20alkyloxy, C₁-20alkyl, C₂-20alkenyl, cyano, nitro, acetamide or halogen;

20 heteroaryl which is a mono or polycyclic system composed of 5- or 6-membered aromatic rings consisting of 1,2, 3 or 4 heteroatoms chosen from N, O, or S and either unsubstituted or substituted with R or independently with hydroxyl, C₁-20alkyloxy, C₁-20alkyl, benzoyl, carboamide, acetamide, halogens, C₂-20alkenyl, cyano, nitro, or haloalkyl directly bonded to the aromatic carbon atoms(s);

25

C₆-14 arylC₁-20alkyl of the formula:

30



wherein the aromatic ring is optionally and independently substituted with R⁷ and R⁸ wherein R⁷ and R⁸ are H,

- 71 -

- CH₃,
 C₂H₅,
 carboxamido,
 5 C₁-C₆ alkylthio,
 C₁-C₆ alkylsulfinyl,
 C₁-C₆ alkylsulfonyl,
 OCH₃,
 NH₂,
 10 CH₃NH,
 (CH₃)₂N,
 OH,
 NO₂,
 CN,
 15 F,
 acetamido,
 Cl,
 OC₂H₅,
 CF₃,
 20 isopropyl, or
 isobutyl; n equals 1-10 and the C₁-20alkyl portion is optionally
 substituted with R⁵;

HeteroarylC₁-20alkyl of the formula:



wherein X equals O, S, or NR; and n equals 1-10;

C₁-20alkylsulfonylC₁-20alkyl,

- 72 -

C₁-20alkylthioC₁-20alkyl,
C₁-20alkylsulfinylC₁-20alkyl of the formula:

5 -(CH₂)_nS(O)_p-R⁹ wherein R⁹ is
C₀-10alkylC₆-14aryl,
CH₃,
C₂H₅,
C₃H₇,
10 C₄H₉,
isopropyl,
isobutyl,
sec-butyl,
t-butyl,
15 isopentyl,
neopentyl, or
ixohexyl; n equals 1-15 and p=0-2;

C₁-20alkyloxycarbonylC₁-20alkyl of the formula:

20
$$-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}-OR^{10}$$
 wherein R¹⁰
is:
CH₃,
C₂H₅,
25 C₃H₇,
C₄H₉, or
C₅H₁₁; and n equals 1-20;

CarboxylC₁-20alkyl of the formula:

30
$$-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}-OH; n = 1-20;$$

C₁-20alkylcarbonylC₁-20alkyl of the formula

- 73 -


$$-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}-(CH_2)_mCH_3, n \text{ equals } 1-20;$$

$$m \text{ equals } 0-19;$$

C₃-20cycloalkylC₁-20alkyl of the formula:

$$-(CH_2)_n-(\text{cycloalkyl})$$
 wherein the cycloalkyl portion is a monocyclic, bicyclic, or polycyclic hydrocarbon of up to 20 carbon atoms wherein the rings are optionally substituted with R¹; and n = 1-20;

ArylC₁-20alkyloxycarbonylC₁-20alkyl of the formula:



wherein n = 1-20;

HeteroarylC₁-20alkyloxycarbonylC₁-20alkyl of the formula:

$$-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}-O-(CH_2)_n-\text{Heteroaryl}$$
 wherein Heteroaryl is as defined and n = 1-20;

haloC₁-20alkyl of the formula:


$$-(CH_2)_n-CH_2X$$
 wherein X equals Br, Cl, F or I; n is 1-19;

hydroxylC₁-20alkyl of the formula:

$$-(CH_2)_nCH_2OH; n \text{ is } 1-19;$$

halohydroxylC₁-20alkyl of the formula:

- 74 -



5


 $n = 1-18$ $q = 0-18$ $n + q = 0-18$ and

X equals Br, Cl, F or I;


10

ThiosulfatoC₁₋₂₀alkyl of the formula: $-(\text{CH}_2)_n\text{CH}_2\text{SSO}_3\text{Na}$; n is 1-19;phosphonoC₁₋₂₀alkyl of the formula: $-(\text{CH}_2)_n\text{P}(\text{O})(\text{OR})_2$ wherein R is lower alkyl and n is 1-20;


15

ArylC₁₋₂₀alkyloxyC₁₋₂₀alkyl of the formula:

20



ArylcarbonylarylC₁₋₂₀alkyl of the formula:

25

DiarylC₁₋₂₀alkyl of the formula:

30

- 75 -

TriarylC₁-20alkyl of the formula:Aryl C₂-20alkenyl of the formula:R⁴ is

H,
 C₁-20alkyl,
 25 C₆ aryl wherein aryl is a monocyclic system composed of 6-membered aromatic rings either unsubstituted or substituted with R wherein R is H, C₁-6 alkyl, arylC₁-20alkyl with the alkyl groups unsubstituted or substituted with hydroxyl, C₁-8alkyloxy, carboxy C₀-10alkyl, or halogen or aryl directly substituted independently with amino, mono C₁-C₄ alkylamino, di C₁-C₄ alkylamino, mono C₁-C₄ alkylaminoaryl, di C₁-C₄ alkylaminoaryl, hydroxyl, haloC₁-20alkyl, carboxamido,
 30 benzoyl, C₁-20alkyloxy, C₁-20alkyl, C₂-20alkenyl, cyano, nitro, acetamide or halogen; or

- 76 -

heteroaryl;

R⁵ can be the same or different when x is greater than one and is;



5

H, or

C₁₋₁₂alkyl;

W is:

10



15

x is an integer from 1-10;


and the dashes indicate a double bond is optionally present.

20

3. A compound according to Claim 1 and the
pharmaceutically acceptable salts thereof, wherein,

25

A is:

R¹ is:

30

H,
methyl or ethyl;


R² is:

H, or
C₁₋₁₂ alkyl;


- 77 -

R³ is:

- 5 H,
C₁-20 alkyl,
C₆-14 aryl,
heteroaryl,
C₆-14 arylC₁-20alkyl,
10 heteroarylC₁-20alkyl,
C₁-20alkylthioC₁-20alkyl,
C₁-20alkyloxycarbonylC₁-20alkyl,
carboxylC₁-20alkyl,
C₁-20 alkylcarbonylC₁-20alkyl,
15 C₃-20cycloalkyl,
C₃-20cycloalkylC₁-20alkyl,
C₆-14 arylC₁-20alkyloxycarbonylC₁-20alkyl,
heteroarylC₁-20alkyloxycarbonylC₁-20alkyl, -
haloC₁-20alkyl,
hydroxyC₁-20alkyl,
20 halohydroxyC₁-20alkyl,
thiosulfatoC₁-20alkyl,
C₆-14 arylcarbonylC₆-14arylC₁-20alkyl,
C₆-14 arylC₁-20alkyloxyC₁-20alkyl,
C₁-20cycloalkylC₁-20alkyl,
25 diarylC₁-20alkyl of the formula:

triarylC₁-20alkyl of the formula:

- 78 -



, n equals 1-19; or

C₂-20 alkenyl;R⁴ is:

H,

C₁-20 alkyl,

C₆-14 aryl wherein aryl is a monocyclic system composed of 6-membered aromatic rings either unsubstituted or substituted with R wherein R is H, C₁-6 alkyl, arylC₁-20alkyl with the alkyl groups unsubstituted or substituted with hydroxyl, C₁-8alkyloxy, carboxy C₀-10alkyl, or halogen or aryl directly substituted independently with amino, mono C₁-C₄ alkylamino, di C₁-C₄ alkylamino, mono C₁-C₄ alkylaminoaryl, di C₁-C₄ alkylaminoaryl, hydroxyl, haloC₁-20alkyl, carboxamido, benzoyl, C₁-20alkyloxy, C₁-20alkyl, C₂-20alkenyl, cyano, nitro, acetamide or halogen; or heteroaryl.

4. A compound according to Claim 3 and the pharmaceutically acceptable salts thereof wherein:

R¹ is:

H,

methyl, or

ethyl;

- 79 -

R² is:

5 H,
 methyl,
 ethyl, linear or branched:
 propyl,
 butyl,
10 pentyl,
 hexyl, or heptyl;

R³ is:

15 t-butyl,
 2,2-diphenylethyl,
 3-thienyl,
 2-thienyl,
 11-(isopropylthio)undecyl,
 7-(carbomethoxy)heptyl,
20 1-(1-(4-isobutylphenyl)-ethyl),
 7-(carboxy)heptyl,
 acetylmethyl,
 1-adamantylmethyl,
 2-thienylmethyl,
25 2-(carbobenzyloxy)ethyl,
 3,4-dimethoxyphenyl,
 phenyl,
 5-bromopentyl,
 phenylthiomethyl,
30 t-butylthiomethyl,
 3-methyl-2-thienyl,
 5-methyl-2-thienyl,
 11-hydroxyundecyl,
 1-(4-nitrophenyl)ethyl,

- 80 -

isopropylthiomethyl,
5-(thiosulfato)pentyl,
benzyloxymethyl,
5 carbomethoxymethyl,
diphenylmethyl,
triphenylmethyl,
2-furyl,
4-isopropylphenyl,
10 cyclohexylmethyl,
4-methylcyclohexyl,
3-(3-indolyl)propyl,
3-Indolylmethyl,
4-isobutylphenyl,
15 4-nitrophenyl,
3-nitrophenyl,
3-acetamidomethyl,
4-ethoxyphenyl,
hexadecyl,
stearyl,
20 3,5-Bis(trifluoromethyl)benzyl,
3-cyanophenyl,
heptafluoropropyl,
4-benzoylphenyl,
5-benzotriazolyl,
25 3,5-difourophenyl,
bis(4-isopropylphenyl)methyl,
2-hydroxyphenyl,
phenylvinyl,
2-hydroxy-3,3,3-trichloropropyl,
30 methyl,
allyl,
n-propyl,
n-octyl,
isopropyl,

- 81 -

(isopropylthio)methyl,
isobutyl,
ethyl,
5 2,2,2-triphenylethyl,
benzyl,
octadecyl,
2(ethyl)phenyl,
3(chloro)phenyl,
10 4(methyl)phenyl,
2,3(dichloro)phenyl,
2,6(dichloro)phenyl,
4(fluoro)phenyl,
3(methoxy)phenyl,
15 3-(acetamido)phenyl,
3-(Iminodibenz-5-ylmethyl)phenyl,
3-trifluoromethylphenyl,
2(ethoxy)phenyl,
formyl,
2-naphthyl, or
20 2-thiazolyl;

R⁴ is:


H,
25 methyl,
ethyl, linear or branched:
propyl,
butyl,
30 C₆₋₁₄ aryl wherein aryl is a monocyclic system composed
of 6-membered aromatic rings either unsubstituted or
substituted with R wherein R is H, C₁₋₆ alkyl, arylC₁₋₂₀alkyl with the alkyl groups unsubstituted or substituted
with hydroxyl, C₁₋₈alkyloxy, carboxy C₀₋₁₀alkyl, or
halogen or aryl directly substituted independently with

- 82 -

amino, mono C₁-C₄ alkylamino, di C₁-C₄ alkylamino,
 mono C₁-C₄ alkylaminoaryl, di C₁-C₄ alkylaminoaryl,
 hydroxyl, haloC₁-20alkyl, carboxamido, benzoyl, C₁-
 20alkyloxy, C₁-20alkyl, C₂-20alkenyl, cyano, nitro,
 acetamide or halogen; or

heteroaryl;

W is:



5. The compound according to Claim 4 and the
 pharmaceutically acceptable salts thereof, wherein the compound
 is selected from:

4-Methyl-20(trimethylacetamido)5 α -4-aza-pregnan-3-one,

4-Methyl-17 β (trimethylacetamidomethyl)-4-aza-5 α -androstane-3-one,

4-Methyl-17 β (2-thiophenesulfonamidomethyl)-4-aza-5 α -
 androstane-3-one,

17 β (Isopropylthiododecanoylamidomethyl)-4-aza-5 α -androstane-3-one,

4-Methyl-17 β (thiophenecarboxamidomethyl)-4-aza-5 α -androstane-3-one,

17 β (Carbomethoxyoctanoylamidomethyl)-4-methyl-4-aza-5 α -androstane-3-one,

- 83 -

17 β (2-(4-isobutylphenyl)propionamidomethyl)-4-Methyl-4-aza-5 α -androstan-3-one,

5 17 β (8-Carboxyoctanoylamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

17 β (Acetoacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

10 4-Methyl-17 β (2-thiopheneacetamidomethyl)-4-aza-5 α -androstan-3-one,

17 β (3-(carbobenzyloxy)propionamidomethyl)-4-Methyl-4-aza-5 α -androstan-3-one,

15 17 β (3,4-dimethoxyphenylacetamidomethyl)-4-Methyl-4-aza-5 α -androst-3-one,

17 β (Benzenesulfonamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

20 17 β (6-Bromohexanoylamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

25 17 β (12-Hydroxydodecanoylamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

4-Methyl-17 β (2-(4-nitrophenyl)propionamidomethyl)-4-aza-5 α -androstan-3-one,

30 17 β (Isopropylthioacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

4-Methyl-17 β (6-(thiosulfato)hexanoylamidomethyl)-4-aza-5 α -androstan-3-one,

- 5 17 β (Benzyloxyacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,
- 17 β (Carbomethoxyacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,
- 10 17 β (Diphenylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,
- 4-Methyl-17 β (3,3,3-triphenylpropionamidomethyl)-4-aza-5 α -androstan-3-one,
- 15 17 β (2-Furylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,
- 17 β (4-Isopropylphenylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,
- 20 17 β (Cyclohexylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,
- 17 β (3-indolylacetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,
- 25 4-Methyl-17 β (4-Methylcyclohexanecarboxamidomethyl)-4-aza-5 α -androstan-3-one,
- 17 β (4-(3-Indolyl)-butyramidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,
- 30 17 β (4-Isobutylbenzamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

- 85 -

17 β -(Acetoxycetamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

5 17 β -(6-Bromohexanoylamidomethyl)-4-Methyl-4-aza-5 α -androstan-3-one,

20-((3-Acetamido)benzamido)-4-Methyl-4-aza-5 α -pregnan-3-one,

10 17 β -(4-Ethoxybenzamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

17 β -(Iminodibenzyl-5-carboxamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

15 4-Methyl-20-(stearoylamido)-4-aza-5 α -pregnan-3-one,

4-Methyl-17 β -(3,5-bis-(trifluoromethyl)benzamidomethyl)-4-aza-5 α -androstan-3-one,

20 17 β -(3-Cyanobenzamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

17 β -(Benzotriazole-5-carboxamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

25 20-(3,5-difluorobenzamido)-4-methyl-4-aza-5 α -pregnan-3-one,

17 β -(Bis-(4-Isopropyl)phenyl)acetamidomethyl-4-methyl-aza-5 α -androstan-3-one,

30 17 β -(Cinnamoylamidomethyl)-4-methyl-4-aza-5 α -androstan-3-one,

- 86 -

17 β ((3-Hydroxy-4,4,4-trichlorobutyramido)methyl)-4-methyl-4-
aza-5 α -androstan-3-one,

5 17-(2,6-Dichlorobenzamidomethyl)-5- α -4-methyl-4-
azaandrosatan-3-one,

17-(3-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-azaandrostan-
3-one,

10 17-(4-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-azaandrostan-
3-one,

17-(3,3-Diphenylpropionamidomethyl)-5- α -4-methyl-4-
azaandrostan-3-one,

15 17-((3-(Iminodibenz-5-ylmethyl)benzoyl)aminomethyl)-4-
methyl-5- α -4-azaandrostan-3-one,

17-(3-Hydroxy-4,4,4,-trichlorobutyroylamidomethyl))-5- α -4-
methyl-4-azaandrostan-3-one,

20 17-Formamidomethyl-5- α -4-methyl-4-azaandrostan-3-one,

4-Methyl-17-(3,3,3,-triphenylpropionamidomethyl)-5- α -4-
azaandrostan-3-one,

25 20-((Isopropylthio)acetamido)-4-methyl-5- α -4-azapregnan-3-
one,

20-((Isopropylthio)acetamido)-5- α -4-azapregnan-3-one,

4-Methyl-17-((phenylthio)acetamidomethyl)-5- α -4-azaandrostan-
3-one,

30 17-((t-Butylthio)acetamidomethyl)-5- α -4-methyl-4-azaandrostan-
3-one,

17-(3-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-
azaandrostan-3-one,

- 87 -

17-(5-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-
azaandrostan-3-one,

5 4-Methyl-17-(3-(trifluoromethyl)-benzamidomethyl)-5- α -4-
azaandrostan-3-one, or

17-Benzamidomethyl-4-methyl-5- α -4-azaandrostan-3-one.

10 6. The compound according to Claim 4 and the
pharmaceutically acceptable salts thereof, wherein the compound is
selected from:

4-Methyl-20(trimethylacetamido)5 α -4-aza-pregn-1-en-
3-one,

15 4-Methyl-17 β (trimethylacetamidomethyl)-4-aza-5 α -
androst-1-en-3-one,

4-Methyl-17 β (2-thiophenesulfonamidomethyl)-4-aza-5 α -
androst-1-en-3-one,

20 17 β (isopropylthiododecanoylamidomethyl)-4-methyl-4-
aza-5 α -androst-1-en-3-one,

25 4-Methyl-17 β (thiophenecarboxamidomethyl)-4-aza-5 α -
androst-1-en-3-one,

17 β (-8-(Carbomethoxy)octanoylamidomethyl)-4-methyl-4-aza-
5 α -androst-1-en-3-one,

30 17 β (2-(4-Isobutylphenyl)propionamidomethyl)-4-methyl-
4-aza-5 α -androst-1-en-3-one,

17 β (8-Carboxyoctanoylamidomethyl)-4-methyl-4-aza-5 α -androst-
1-en-3-one,

17B(Acetoacetamidomethyl)-4-methyl-4-aza-5 α -androst-1-en-3-one,

5

17B(1-Adamantylacetamidomethyl)-4-methyl-4-aza-5 α -androst-1-en-3-one,

10

4-Methyl-17B(2-thiopheneacetamidomethyl)-4-aza-5 α -androst-1-en-3-one,

17B(3-(Carbobenzyloxy)propionamidomethyl)-4-methyl-4-aza-5 α -androst-1-en-3-one,

15

17B(3,4-Dimethoxyphenylacetamidomethyl)-4-methyl-4-aza-5 α -androst-1-en-3-one,

17B(Benzenesulfonamidomethyl)-4-methyl-4-aza-5 α -androst-1-en-3-one,

20

17B(6-Bromohexanoylamidomethyl)-4-methyl-4-aza-5 α -androst-1-en-3-one,

17B(12-Hydroxydodecanoylamidomethyl)-4-methyl-4-aza-5 α -androst-1-en-3-one,

25

4-Methyl-17B(2-(4-nitrophenyl)propionamidomethyl)-4-aza-5 α -androst-1-en-3-one,

30

17B(Isopropylthioacetamidomethyl)-4-methyl-4-aza-5 α -androst-1-en-3-one,

4-Methyl-17B(6-(thiosulfato)hexanoylamidomethyl)-4-aza-5 α -androst-1-en-3-one,

- 89 -

17 β -(Benzyloxyacetamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

5 17 β -(Carbomethoxyacetamidomethyl)-4-methyl-4-aza-5 α -androst-
1-en-3-one,

17 β -(Diphenylacetamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

10 4-Methyl-17 β -(3,3,3-triphenylpropionamidomethyl)-
4-aza-5 α -androst-1-en-3-one,

15 17 β -(2-Furylacetamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

17 β -(4-Isopropylphenylacetamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

20 17 β -(Cyclohexylacetamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

17 β -(3-Indolylacetamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

25 4-Methyl-17 β -(4-methylcyclohexanecarboxamidomethyl)-4-aza-
5 α -androst-1-en-3-one,

17 β -(4-(3-Indolyl)-butyramidomethyl)-4-methyl-4-aza-
5 α -androst-1-en-3-one,

30 17 β -(4-Isobutylbenzamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

17 β -(Acetoxyacetamidomethyl)-4-methyl-4-aza-5 α -

- 90 -

androst-1-en-3-one,

5 17B(6-Bromohexanoylamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

20-((3-Acetamido)benzamido)-4-methyl-4-aza-5 α -
pregn-1-en-3-one,

10 17B(4-Ethoxybenzamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

17B-(Iminodibenzyl-5-carboxamidomethyl)-4-methyl-4-
aza-5 α -androst-1-en-3-one,

15 4-Methyl-20-(stearoylamido)-4-aza-5 α -pregn-1-en-
3-one,

20 4-Methyl-17B-(3,5-Bis-(trifluoromethyl)benzamido-
methyl)-4-aza-5 α -androst-1-en-3-one,

17B-(3-Cyanobenzamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

25 17B-(Benztriazol-5-carboxamidomethyl)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

20-(3,5-Difluorobenzamido)-4-methyl-4-aza-5 α -pregn-1-en-3-
one,

30 17B-(Bis-(4-Isopropyl)phenyl)acetamidomethyl-4-methyl-aza-5 α -
androst-1-en-one,

17B-(Cinnamoylamidomethyl)-4-Methyl-4-aza-5 α -
androst-1-en-3-one,

- 91 -

- 17 β -((3-Hydroxy-4,4,4,-trichlorobutyramido)methyl)-4-methyl-4-aza-5 α -androst-1-en-3-one,
- 5 17-(2,6-Dichlorobenzamidomethyl)-5- α -4-methyl-4-azaandrosatan-1-en-3-one,
- 17-(3-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-azaandrostan-1-en-3-one,
- 10 17-(4-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-azaandrostan-1-en-3-one,
- 17-(3,3-Diphenylpropionamidomethyl)-5- α -4-methyl-4-azaandrostan-1-en-3-one,
- 15 17-((3-(Iminodibenz-5-ylmethyl)benzoyl)aminomethyl)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-(3-Hydroxy-4,4,4,-trichlorobutyroylamidomethyl))-5- α -4-methyl-4-azaandrostan-1-en-3-one,
- 20 17-Formamidomethyl-5- α -4-methyl-4-azaandrostan-1-en-3-one,
- 4-Methyl-17-(3,3,3,-triphenylpropionamidomethyl)-5- α -4-azaandrostan-1-en-3-one,
- 25 20-((Isopropylthio)acetamido)-4-methyl-5- α -4-azapregnan-1-en-3-one,
- 20-((Isopropylthio)acetamido)-5- α -4-azapregnan-1-en-3-one,
- 4-Methyl-17-((phenylthio)acetamidomethyl)-5- α -4-azaandrostan-1-en-3-one,
- 30 17-((t-Butylthio)acetamidomethyl)-5- α -4-methyl-4-azaandrostan-1-en-3-one,

- 92 -

17-(3-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-
azaandrostan-1-en-3-one,

5 17-(5-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-
azaandrostan-1-en-3-one,

4-Methyl-17-(3-(trifluoromethyl)-benzamidomethyl)-5- α -4-
azaandrostan-1-en-3-one,

10 17-(2,6-Dichlorobenzamidomethyl)-5- α -4-methyl-4-
azaandrosatan-1-en-3-one,

17-(3-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-azaandrostan-
1-en-3-one,

15 17-(4-Nitrobenzoylamidomethyl)-5- α -4-methyl-4-azaandrostan-
1-en-3-one,

17-(3,3-Diphenylpropionamidomethyl)-5- α -4-methyl-4-
azaandrostan-1-en-3-one,

20 17-((3-(Iminodibenz-5-ylmethyl)benzoyl)aminomethyl)-4-
methyl-5- α -4-azaandrostan-1-en-3-one,

17-(3-Hydroxy-4,4,4-trichlorobutyroylamidomethyl)-5- α -4-
methyl-4-azaandrostan-1-en-3-one,

25 17-Formamidomethyl-5- α -4-methyl-4-azaandrostan-1-en-3-one,

4-Methyl-17-(3,3,3-triphenylpropionamidomethyl)-5- α -4-
azaandrostan-1-en-3-one,

20-((Isopropylthio)acetamido)-4-methyl-5- α -4-azapregnan-1-en-
3-one,

30 20-((Isopropylthio)acetamido)-5- α -4-azapregnan-1-en-3-one,

4-Methyl-17-((phenylthio)acetamidomethyl)-5- α -4-azaandrostan-
1-en-3-one,

- 93 -

17-((t-Butylthio)acetamidomethyl)-5- α -4-methyl-4-azaandrostan-1-en-3-one,


5 17-(3-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-azaandrostan-1-en-3-one,

17-(5-Methyl-2-thenoylaminomethyl)-4-methyl-5- α -4-azaandrostan-1-en-3-one,

10 4-Methyl-17-(3-(trifluoromethyl)-benzamidomethyl)-5- α -4-azaandrostan-1-en-3-one, or

17-Benzamidomethyl-4-methyl-5- α -4-azaandrostan-1-en-3-one.

7. A compound according to Claim 1 and the
15 pharmaceutically acceptable salts thereof, wherein
A is:



except when R^2 equals H,
there is a 5 α H
and W equals C(O), R^3
can not be C₁₋₁₂ alkyl

R^1 is:

H,
methyl or ethyl;

R^2 is:

H, or
C₁₋₁₂ alkyl;

30 R^3 is:


H,
C₁₋₂₀ alkyl,
C₆₋₁₄ aryl,
heteroaryl,

- 94 -


aminoC₁-C₄alkyl,
 mono-C₁-C₄alkylaminoC₁-C₄alkyl,
 di C₁-C₄alkylaminoC₁-C₄alkyl,
 5 C₅-14 arylC₁-20alkyl,
 heteroarylC₁-20alkyl,
 C₁-20alkylthioC₁-20alkyl,
 C₁-20alkylsulfonylC₁-20alkyl,
 C₁-20alkylsulfinylC₁-20alkyl,
 10 C₁-20 alkylloxycarbonylC₁-20alkyl,
 carboxyC₁-20alkyl,
 carboC₁-20alkyloxyC₁-20alkyl,
 C₁-20 alkylcarbonylC₁-20alkyl,
 C₁-20cycloalkyl,
 15 C₁-20cycloalkylC₁-20alkyl,
 C₆-14 arylC₁-20alkyloxycarbonylC₁-20alkyl,
 heteroarylC₁-20alkyloxycarbonylC₁-20alkyl,
 haloC₁-20alkyl,
 hydroxylC₁-20alkyl,
 20 halohydroxyC₁-20alkyl,
 thiosulfatoC₁-20alkyl,
 C₆-14 arylC₁-20alkyloxyC₁-20alkyl,
 C₆-14 arylcarbonylC₅-14arylC₁-20alkyl,
 diarylC₁-20 alkyl,
 triarylC₁-20alkyl,
 25 C₂-20 alkenyl,
 phosphonoC₁-20alkyl,
 C₂-20 alkenylC₁-20alkyl,
 heteroarylC₂-20alkenyl,
 C₆-14 arylC₂-20alkenyl,
 30 C₂-20alkynylC₁-20alkyl,
 C₆-14 arylC₂-20alkynylC₁-20alkyl, or
 heteroarylC₂-20alkynylC₁-20alkyl;

W is:

- 95 -



5



10 8. A compound according to Claim 7 and the pharmaceutically acceptable salts thereof wherein:

R¹ is:

15 H,
methyl,
ethyl,

R² is:

20 H,
methyl,
ethyl, linear or branched:
propyl,
butyl,
pentyl,
hexyl, or
25 heptyl;

R³ is:

30 t-butyl,
3-thienyl,
2-thienyl,
4-pyrdinyl,
2-pyridinyl,
3-pyridinyl,
(2(3-benzamido)phenyl)ethyl,
t-trifluoromethyl,

- 96 -

5 2,3-difluorophenyl,
2-methylphenyl,
2,3-dimethylphenyl,
cinnamoyl,
formyl,
2-propyl,
3-methylbutyl,
2-(carbomethoxy)-1-cyclopentenyl,
10 2,6-difluorophenyl,
2,3-difluorophenyl,
2,6-dichlorophenyl,
t-butylmethyl,
t-butylthiomethyl,
15 (phenyl)methyl,
phenylthiomethyl,
11-(isopropylthio)undecyl,
7-(carbomethoxy)heptyl,
3-carboxy-3-methylbutyl,
3-(carbomethoxy)-3-methylbutyl,
20 3-(carbomethoxy)-2,2-dimethylpropyl,
1-(1-(4-isobutylphenyl))ethyl,
7-(carboxy)heptyl,
acetoxymethyl,
1-methyl-2-pyrrole,
25 5-(diethylphosphono)pentyl,
2-(4'-fluoro-3,5,3'-trimethylbiphen-2-yl)ethyl,
2-phenylpropyl,
2,2-dimethylethylenyl,
4-benzyloxyphenyl,
30 2,4,4-trimethylpentyl,
benzylthiomethyl,
benzthiophen-3-yl,
2-hydroxy-2-propyl,
2-acetoxy-2-propyl,


- 97 -

1-adamantylmethyl,
2-thienylmethyl,
2-(phenyl)propyl,
5 2-(carbobenzyloxy)ethyl,
3,4-dimethoxyphenyl,
-phenyl,
5-bromopentyl,
11-hydroxyundecyl,
10 1-ethyl-4-nitrobenzene-1-yl,
isopropylthiomethyl,
5-(thiosulfato)pentyl,
benzyloxymethyl,
carbomethoxymethyl,
15 diphenylmethyl,
triphenylmethyl,
1-methyl-2-pyrrolyl,
3-carboxy-3-methylbutyl,
2-furyl,
5-(Diethylphosphono)pentyl,
20 4-isopropylphenyl,
cyclohexylmethyl,
4-methylcyclohexyl,
3-(3-Indolyl)propyl,
3-Indolylmethyl,
25 4-isobutylphenyl,
4-nitrophenyl,
3-nitrophenyl,
2,3-difluorophenyl,
3-fluoro-2-methylphenyl,
30 2-fluorophenyl,
2,2-dimethylethylenyl,
3-acetamidomethyl,
4-ethoxyphenyl,
3-(2-nitrophenoxy)propyl,

- 98 -

5 hexadecyl,
 stearyl,
 3,5-Bis(trifluoromethyl)phenyl,
 3-cyanophenyl,
 4-cyanophenyl,
 2,4,4-trimethylpentyl,
 t-butylmethyl,
 benzyl,
 10 heptafluoropropyl,
 5-benztriazolyl,
 3,5 difluorophenyl,
 Bis(4-isopropylphenyl)methyl,
 2-hydroxyphenyl,
 15 2-phenylvinyl, or
 2-hydroxy-3,3,3-trichloropropyl;

W is:



25 9. The compound according to Claim 8 and the
 pharmaceutically acceptable salts thereof, wherein the compound is
 selected from:

30 17B(12-(t-Butylthio)dodecanoylamido)-4-methyl-4-aza-
 5 α -androstane-3-one,

4-Methyl-17B(8-(carbomethoxy)octanoylamido)-4-aza-5 α -androstane-3-
 one,

17B(Isopropylthiododecanoylamido)-4-methyl-4-aza-5 α -

- 99 -

androstan-3-one,

4-Methyl-17B(3-thienylamido)-4-aza-5 α -androstan-3-one,

17-Benzoylamido-5- α -4-methyl-4-azaandrostan-3-one,

17-(2-Thiophenesulfonamido)-5- α -4-methyl-4-azaandrostan-3-one,

4-Methyl-17-(phenylthioacetamido)-5- α -4-methyl-4-azaandrostan-3-one,

4-Methyl-17-(4-methylpentanoylamido)-5- α -4-azaandrostan-3-one,

4-Methyl-17-(3-thenoylamino)-5- α -4-azaandrostan-3-one,

17-(3-(4'-Fluoro-3,5,3'-trimethylbiphen-2-yl)propionamido)-4-methyl-5- α -4-azaandrostan-3-one,

17-(6-(Diethylphosphono)hexanoylamino)-4-methyl-5- α -4-azaandrostan-3-one,

17-((t-Butylthio)acetamido)-4-methyl-5- α -4-azaandrostan-3-one,

4-Methyl-17-(3-thiophenacetamido)-5- α -4-azaandrostan-3-one,

4-Methyl-17-(4-nitrobenzamido)-5- α -4-azaandrostan-3-one,

4-Methyl-17-(3-nitrobenzamido)-5- α -4-azaandrostan-3-one,

17-(2-Fluorobenzamido)-4-methyl-5- α -4-azaandrostan-3-one,

17-(4-cyanobenzamido)-4-methyl-5- α -4-azaandrostan-3-one,

17-(Benzthiophen-3-ylacetamido)-4-methyl-5- α -4-azaandrostan-3-one,

- 100 -

- 4-Methyl-17-(2-thiophenecarboxamido)-5- α -4-azaandrostan-3-one,
- 5 17-(1-Methyl-2-pyrrolicarboxamido)-4-methyl-5- α -4-azaandrostan-3-one,
- 17-(4-Carboxy-4-methylpentanoylamido)-4-methyl-5- α -4-azaandrostan-3-one,
- 10 17-(4-Carbomethoxy-4-methylpentanoylamido)-4-methyl-5- α -4-azaandrostan-3-one,
- 17-(4-Carbomethoxy-3,3-dimethylbutyroylamido)-4-methyl-5- α -4-azaandrostan-3-one,
- 15 4-Methyl-17-(3-phenylbutyroylamido)-5- α -4-azaandrostan-3-one,
- 17-(2,3-Difluorobenzoylamido)-4-methyl-5- α -4-azaandrostan-3-one,
- 20 4-Methyl-17-(2-methylbenzoylamido)-5- α -4-azaandrostan-3-one,
- 17-(2,3-Dimethylbenzamido)-4-methyl-5- α -4-azaandrostan-3-one,
- 17-Cinnamoylamido-4-methyl-5- α -4-azaandrostan-3-one,
- 25 17-(3,3-Dimethylacrylamido)-4-methyl-5- α -4-azaandrostan-3-one,
- 17-(3,4-Dimethoxybenzamido)-4-methyl-5- α -4-azaandrostan-3-one,
- 30 17-(Acetoxylacetamido)-4-methyl-5- α -4-azaandrostan-3-one,
- 4-Methyl-17-(4-(2-nitrophenoxy)-butyroylamido)-5- α -4-azaandrostan-3-one,

- 101 -

17-Isobutyroylamido-4-methyl-5- α -4-azaandrostan-3-one,

5 17-(3,3-Dimethyl-4-(1-(4-isobutylphenyl)ethoxy)benzamido)-4-methyl-5- α -4-aza--androstan-3-one,

17-(4-Benzoyloxybenzamido)-methyl-5- α -4-azaandrostan-3-one,

10 4-Methyl-17-(3-fluoro-2-methylbenzamido)-5- α -4-azaandrostan-3-one,

4-Methyl-17-(3,5,5,-trimethylhexanoylamino)-5- α -4-azaandrostan-3-one,

17-((Benzylthio)acetamido)-4-methyl-5- α -4-azaandrostan-3-one,

15 17-(2-Acetoxyisobutyramido)-4-methyl-5- α -4-azaandrostan-3-one,

4-Methyl-17-trifluoroacetamido-5- α -4-azaandrostan-3-one,

20 17-(2-Hydroxyisobutyramido)-4-methyl-5- α -4-azaandrostan-3-one,

17-(Isonicotinoylamino)-4-methyl-5- α -4-azaandrostan-3-one,

17-(t-Butylacetamido)-4-methyl-5- α -4-azaandrostan-3-one,

25 4-Methyl-17-phenylacetamido-5- α -4-azaandrostan-3-one,

4-Methyl-17-(picolinoylamido)-5- α -4-azaandrostan-3-one,

4-Methyl-17-(nicotinoylamido)-5- α -4-azaandrostan-3-one,

30 17-(3-((3-Benzamido)phenyl)propionamido)-4-methyl-5- α -4-azaandrostan-3-one,

17-Formamido-4-methyl-5- α -4-azaandrostan-3-one,

- 102 -

17-(2-(Carbomethoxy)-1-cyclopentenylcarboxamido)-4-methyl-5- α -4-
azaandrostan-3-one,

5

17-(2,6-Difluorobenzamido)-4-methyl-5- α -4-azaandrostan-3-one, or

17-(2,3-Difluorobenzamido)-4,7-dimethyl-5- α -4-azaandrostan-3-one.

10

10. The compound according to Claim 8 and the
pharmaceutically acceptable salts thereof, wherein the compound is
selected from:

15

17 β -(12-(*t*-Butylthio)dodecanoylamido)-4-methyl-4-aza-
5 α -androst-1-en-3-one,

4-Methyl-17 β -(8-(carbomethoxy)octanoylamido)-4-aza-5 α -androst-1-en-
3-one,

20

17 β -(Isopropylthiododecanoylamido)-4-methyl-4-aza-5 α -
androst-1-en-3-one,

17-Benzoylamido-5- α -4-methyl-4-azaandrostan-1-en-3-one,

25

17-(2-Thiophenesulfonamido)-5- α -4-methyl-4-azaandrostan-1-en-3-one,

4-Methyl-17-(phenylthioacetamido)-5- α -4-methyl-4-azaandrostan-1-en-
3-one,

30

4-Methyl-17-(4-methylpentanoylamido)-5- α -4-azaandrostan-1-en-3-one,

4-Methyl-17-(3-thenoylamino)-5- α -4-azaandrostan-1-en-3-one,

- 103 -

- 17-(3-(4'-Fluoro-3,5,3'-trimethylbiphen-2-yl)propionamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 5 17-(6-(Diethylphosphono)hexanoylamino)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-((t-Butylthio)acetamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 10 4-Methyl-17-(3-thiophenacetamido)-5- α -4-azaandrostan-1-en-3-one,
- 4-Methyl-17-(4-nitrobenzamido)-5- α -4-azaandrostan-1-en-3-one,
- 4-Methyl-17-(3-nitrobenzamido)-5- α -4-azaandrostan-1-en-3-one,
- 15 17-(2-Fluorobenzamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-(4-cyanobenzamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 20 17-(Benzthiophen-3-ylacetamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 4-Methyl-17-(2-thiophenecarboxamido)-5- α -4-azaandrostan-1-en-3-one,
- 17-(1-Methyl-2-pyrrolicarboxamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 25 en-3-one,
- 17-(4-Carboxy-4-methylpentanoylamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 30 17-(4-Carbomethoxy-4-methylpentanoylamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-(4-Carbomethoxy-3,3-dimethylbutyroylamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,

- 104 -

- 4-Methyl-17-(3-phenylbutyroylamido)-5- α -4-azaandrostan-1-en-3-one,
- 5 17-(2,3-Difluorobenzoylamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 4-Methyl-17-(2-methylbenzoylamido)-5- α -4-azaandrostan-1-en-3-one,
- 10 17-(2,3-Dimethylbenzamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-Cinnamoylamido-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-(3,3-Dimethylacrylamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 15 17-(3,4-Dimethoxybenzamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-(Acetoxylacetamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 20 4-Methyl-17-(4-(2-nitrophenoxy)-butyroylamido)-5- α -4-azaandrostan-1-en-3-one,
- 17-Isobutyroylamido-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 25 17-(3,3-Dimethyl-4-(1-(4-isobutylphenyl)ethoxy)benzamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-(4-Benzyloxybenzamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 30 4-Methyl-17-(3-fluoro-2-methylbenzamido)-5- α -4-azaandrostan-1-en-3-one,
- 4-Methyl-17-(3,5,5-trimethylhexanoylamino)-5- α -4-azaandrostan-1-en-3-one,


- 105 -

- 17-((Benzylthio)acetamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 5 17-(2-Acetoxyisobutyramido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 4-Methyl-17-trifluoroacetamido-5- α -4-azaandrostan-1-en-3-one,
- 17-(2-Hydroxyisobutyramido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 10 one,
- 17-(Isonicotinoylamino)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-(t-Butylacetamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 15 4-Methyl-17-phenylacetamido-5- α -4-azaandrostan-1-en-3-one,
- 4-Methyl-17-(picolinoylamido)-5- α -4-azaandrostan-1-en-3-one,
- 4-Methyl-17-(nicotinoylamido)-5- α -4-azaandrostan-1-en-3-one,
- 20 17-(3-((3-Benzamido)phenyl)propionamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-Formamido-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 25 17-(2-(Carbomethoxy)-1-cyclopentenylcarboxamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 17-(2,6-Difluorobenzamido)-4-methyl-5- α -4-azaandrostan-1-en-3-one,
- 30 or
- 17-(2,3-Difluorobenzamido)-4,7-dimethyl-5- α -4-azaandrostan-1-en-3-one.

- 106 -

11. A compound according to Claim 1 and the
 5 pharmaceutically acceptable salts thereof, wherein:

A is:



R¹ is:

15 H,
methyl or ethyl;

R² is:


20 H, or
C₁-12 alkyl;

R³ is:


25 H,
C₁-20 alkyl,
C₆-14 aryl,
heteroaryl,
C₆-14 arylC₁-20alkyl,
heteroarylC₁-20alkyl,
30 C₁-20alkylthioC₁-20alkyl,
C₁-20alkylsulfinylC₁-20alkyl,
C₁-20alkylsulfonylC₁-20alkyl,
C₁-20alkyloxycarbonylC₁-20alkyl,
carboxylC₁-20alkyl,

- 107 -

C₁-20 alkylcarbonylC₁-20alkyl,
 C₃-20cycloalkyl,
 C₃-20cycloalkylC₁-20alkyl,
 5 C₆-14 arylC₁-20alkyloxycarbonylC₁-20alkyl,
 heteroarylC₁-20alkyloxycarbonylC₁-20alkyl,
 haloC₁-20alkyl,
 hydroxyC₁-20alkyl,
 halohydroxyC₁-20alkyl,
 10 thiosulfatoC₁-20alkyl,
 C₆-14 arylC₁-20alkyloxyC₁-20alkyl,
 C₆-14 arylcarbonylC₆-14arylC₁-20alkyl,
 diarylC₁-20alkyl of the formula:



20 triarylC₁-20alkyl of the formula:



30 C₂-20 alkenyl,
 C₂-20 alkenylC₁-20alkyl,
 heteroarylC₂-20alkenyl,
 C₆-14 arylC₂-20alkenyl,
 C₂-20alkynylC₁-20alkyl,

- 108 -

C₆-14 arylC₂-20alkynylC₁-20alkyl, or
heteroarylC₂-20alkynylC₁-20alkyl;

5 R⁴ is:

H,
C₁-20 alkyl,
C₆-14 aryl wherein aryl is a monocyclic system composed
10 of 6-membered aromatic rings either unsubstituted or
substituted with R wherein R is H, C₁-6 alkyl, arylC₁-
20alkyl with the alkyl groups unsubstituted or substituted
with hydroxyl, C₁-8alkyloxy, carboxy C₀-10alkyl, or
halogen or aryl directly substituted independently with
15 amino, mono C₁-C₄ alkylamino, di C₁-C₄ alkylamino,
mono C₁-C₄ alkylaminoaryl, di C₁-C₄ alkylaminoaryl,
hydroxyl, haloC₁-20alkyl, carboxamido, benzoyl, C₁-
20alkyloxy, C₁-20alkyl, C₂-20alkenyl, cyano, nitro,
acetamide or halogen; or
heteroaryl;


20

R⁵ can be the same or different when x is greater than 1 and is:

H, or
C₁-20 alkyl;

25

W is:



x is an integer from 1-10.

12. A compound according to Claim 11 and the
pharmaceutically acceptable salts thereof, wherein

- 109 -

R¹ is:

5 H,
 methyl, or
 ethyl;

R² is:

10 H,
 methyl,
 ethyl, linear or branched:
 propyl,
 butyl,
15 pentyl,
 hexyl, or heptyl;

R³ is:

20 t-butyl,
 3-thienyl,
 2-thienyl,
 11-(isopropylthio)undecyl,
 7-(carbomethoxy)heptyl,
 1-(1-(4-isobutylphenyl)-)ethyl,
25 7-(carboxy)heptyl,
 acetylmethyl,
 1-adamantylmethyl,
 2-thienylmethyl,
 2-(carbobenzyloxy)ethyl,
30 3,4-dimethoxyphenylmethyl,
 phenyl,
 5-bromopentyl,
 11-hydroxyundecyl,
 1-(4-nitrophenyl)ethyl,

- 110 -

isopropylthiomethyl,
5-(thiosulfato)pentyl,
benzyloxymethyl,
5 carbomethoxymethyl,
diphenylmethyl,
triphenylmethyl,
2-furyl,
4-isopropylphenyl,
10 cyclohexylmethyl,
4-methylcyclohexyl,
3-(3-indolyl)propyl,
3-Indolylmethyl,
4-isobutylbenzyl,
15 4-nitrobenzyl,
3-acetamidomethyl,
4-ethoxybenzyl,
hexadecyl,
(isopropylthio)methyl,
stearyl,
20 3,5-Bis(trifluoromethyl)benzyl,
3-cyanobenzyl,
heptafluoropropyl,
4-benzoylbenzyl,
5-benzotriazolyl,
25 3,5-difourobenzyl,
bis(4-isopropylphenyl)methyl,
2-hydroxybenzyl,
phenylvinyl,
2-hydroxy-3,3,3-trichloropropyl,
30 methyl,
allyl,
n-propyl,
n-octyl,
isopropyl,

- 111 -

5 isobutyl,
ethyl,
benzyl,
octadecyl,
2(ethyl)phenyl,
3(chloro)phenyl,
4(methyl)phenyl,
2,3(dichloro)phenyl,
10 4(fluoro)phenyl,
3(methoxy)phenyl,
2(ethoxy)phenyl,
2-naphthyl, or
2-thiazolyl;

15

R⁴ is:

H,
methyl,
ethyl, linear or branched:
20 propyl,
butyl,
C₆ aryl wherein aryl is a monocyclic system composed of
6-membered aromatic rings either unsubstituted or
substituted with R wherein R is H, C₁-6 alkyl, arylC₁-
25 20alkyl with the alkyl groups unsubstituted or substituted
with hydroxyl, C₁-8alkyloxy, carboxy C₀-10alkyl, or
halogen or aryl directly substituted independently with
amino, mono C₁-C₄ alkylamino, di C₁-C₄ alkylamino,
mono C₁-C₄ alkylaminoaryl, di C₁-C₄ alkylaminoaryl,
30 hydroxyl, haloC₁-20alkyl, carboxamido, benzoyl, C₁-
20alkyloxy, C₁-20alkyl, C₂-20alkenyl, cyano, nitro,
acetamide or halogen; or

heteroaryl;

- 112 -

R⁵ can be the same or different when x is greater than 1 and is:

H,
methyl,
ethyl,
propyl,
butyl, or
pentyl.

5

10

13. The compound according to Claim 12, selected from:

4-Methyl-20-(4-Nitrobenzamidomethyl)-4-aza-5 α -pregnan-3-one,

15

20-(3,4-Dimethoxyphenylacetamidomethyl)-4-methyl-4-aza-5 α -pregnan-3-one,

4-Methyl-20-(Palmitoylamidomethyl)-4-aza-5 α -pregnan-3-one,

20

20-(Heptafluorobutyramidomethyl)-4-methyl-4-aza-5 α -pregnan-3-one, or

4-Methyl-20(salicylamidomethyl)-4-aza-5 α -pregnan-3-one.

25

14. The compound according to Claim 12, selected from:

4-Methyl-20-(4-nitrobenzamidomethyl)-4-aza-5 α -1-pregnen-3-one,

30

20-(3,4-Dimethoxyphenylacetamidomethyl)-4-methyl-4-aza-5 α -1-pregnen-3-one,

- 113 -

4-Methyl-20-(palmitoylaminomethyl)-4-aza-5 α -1-pregnen-3-one,

5 20(Heptafluorobutyramidomethyl)-4-methyl-4-aza-5 α -1-pregnen-3-one, or

4-Methyl-20(Salicylamidomethyl)-4-aza-5 α -1-pregnen-3-one.

10

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in a pharmaceutically acceptable carrier therefor.

15

16. A method of treating benign prostatic hyperplasia, acne, female hirsutism, male pattern baldness, androgenic alopecia, prostatitis, and/or preventing prostatic carcinoma in a human host in need of such treatment comprising the step of administering to said host a therapeutically effective amount of the compound defined in Claim 1.

20

17. The method of Claim 16 wherein said compound is an inhibitor of 5 α -reductase 1.

25

18. The method of Claim 16 wherein said compound is an inhibitor of 5 α -reductase 2.

30

19. The method of Claim 16 wherein said compound is a dual inhibitor of both 5 α -reductase 1 and 2.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/04633

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K31/435 C07D 221/02

US CL :546/77; 514/284

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 546/77; 514/284

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS online structure search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Jour. Clinical Endoc. and METAB, Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, a steroid 5 α reductase inhibitor, alone and in combination with topical minoxidil in the balding stump-tail macaque, pages 345-350. See page 345, para. bridging cols. 1-2, last 3 lines.	16-19
A	J. Org. Chem., Vol. 46, 1981, Back "Oxidation of Azasteroid Lactams and Alcohols with Benzeneselenic Anhydride" pages 1442-6	1-19

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 JULY 1993

Date of mailing of the international search report

AUG 17 1993

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Authorized officer


 D.G. DAUS

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/04633

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Jour. Med. Chem., Vol. 27, 1984, Rasmusson et al. "Azasteroids as inhibitors of rat prostatic 5 α reductase" pages 1690-1701	1
X	Jour. Med. Chem., Vol. 29, 1986 Rasmusson et al. "Azasteroids structure-activity relationships for inhibition of 5 α reductase and of androgen receptor binding" pages 2298-2315. See page 2300 compounds 10A2, 10BA and rest of list.	1
A	E, P, B 0200 859 (Cainelli et al.) 12 November 1986. See entire document.	1
X	US, A, 4,377,584 (Rasmusson et al.) 22 March 1983. See claims 1, 14, 16-18	1, 2, 7-10, 15-19
A	US, A, 4,760,071 (Rasmusson et al.) 26 July 1988. See entire document.	1
A	US, A, 4,882,319 (Holt et al.) 21 November 1989. See entire document.	1
A	US, A, 5,049,562 (Rasmusson et al.) 17 September 1991. See entire document.	1
X, P	US, A, 5,116,983 (Bhattacharya et al.) 26 May 1992. See entire document.	1, 2, 7-10, 15-19
A	US, A, 5,110,939 (Holt et al.) 5 May 1992. See entire document.	1
A	Jour. Organic Chem. Vol. 54; 1989 Back et al. "N Chloro Azasteroids A Novel Class of Reactive Steroid Analogues. Preparation, Reaction with Thiols and Photochemical Conversion to Electrophilic Nacyol Imines" pages 1904-10	1
A	US, A, 4,859,681 (Rasmusson et al.) 22 August 1989.	1-19

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.